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Abstract
The orexinergic system is a key regulator of the sleep-wake cycle, and as such,
presents a prominent target for drug development against ailments such as insomnia
and narcolepsy. The system comprises two G protein-coupled receptors (GPCR),
OX1 and OX2, and two neuropeptides, orexin-A and orexin-B. In the beginning of the
study presented here, several antagonists (blockers) of the receptors were available
but drug-like agonists (activators) were not. The search for the latter was hampered
by the poor understanding how the endogenous ligands, the orexin peptides, activate
their receptors.
The main objective for the thesis research was to elucidate the binding mode
of orexin peptides at their cognate receptors, along with the activation determinants,
using both computational and traditional experimental methods.
We produced homology models for the OX1 receptor based on related GPCRs,
and subsequently adopted the orexin receptor structures reported during the study.
Peptide binding mode was probed through rigid-body docking, which resulted in two
alternative binding modes. These were followed up by extensive molecular dynamics
simulations within membrane environment, accompanied with simulations of small-
molecule binding. Deriving from the simulations, we proposed a single, well-defined
binding mode for the orexin peptide C-terminus within the canonical GPCR binding
site. In addition, we observed that the small-molecular antagonist was remarkably
stable within the binding site, whereas the recently reported agonist Nag26 was more
mobile. The pool of simulations allowed us to observe differences between the
agonists and the antagonist, leading to suggestions on determinants of agonist and
antagonist binding.
To assess the bioactive conformation of orexin peptides, we produced
conformationally constrained orexin peptide variants. These showed that the
stabilization of the straight -helical conformation of the orexin-A is detrimental to
potency, but not necessary to efficacy, at least with the utilized stapled peptides and
-aminoisobutyric acid insertions at the tested sites. We assume that the
modifications were directly incompatible with the binding interactions, or the
stabilized conformation was sub-optimal.
The literature review focuses on the functions and characteristics  of  GPCRs




Oreksiinijärjestelmä on tärkeä uni–valverytmin säätelijä ja näin ollen
kiinnostava lääkekehityskohde muun muassa nukahtamis- ja narkolepsialääkkeille.
Järjestelmään kuuluu kaksi G-proteiinikytkentäistä reseptoria (GPCR), OX1 ja OX2,
sekä kaksi neuropeptidiä, oreksiini-A ja -B. Väitöskirjassa esitetyn tutkimuksen
alussa tunnettiin useita reseptoriantagonisteja (salpaajia), mutta lääkkeenkaltaisia
agonisteja (aktivaattoreita) ei tunnettu. Endogeenisten agonistien, eli oreksiini-
peptidien, sitoutumistapaa reseptoreihin ei tunnettu, mikä haittasi etenkin agonistien
etsintää.
Väitöstutkimuksen päätavoite oli selvittää oreksiinipeptidien sitoutumistapa
oreksiinireseptoreihin ja reseptorin aktivoitumiselle oleelliset vuorovaikutukset.
Tähän käytettiin sekä tietokoneavusteisia että perinteisiä kokeellisia menetelmiä.
Tuotimme OX1 reseptorista malleja ensin läheisiin reseptorirakenteisiin
pohjautuen, ja kun oreksiinireseptorien rakenteita julkaistiin, hyödynsimme niitä.
Peptidien sitoutumista selvitettiin telakoimalla. Tämän pohjalta esitimme kaksi
vaihtoehtoista sitoutumistapaa, joille ajoimme kattavia molekyylidynaamisia
simulaatioita. Lisäksi simuloimme pienmolekyylien sitoutumista. Simulaatioiden
pohjalta esitimme oreksiinipeptidien C-terminaalille yhden tarkasti muotoillun
sitoutumistavan reseptorin sitoutumistaskuun. Simulaatiot osoittivat myös, että
antagonist suvoreksantin sitoutuminen on hyvin vakaata, mikä puolestaan ei pitänyt
paikkaansa hiljattain julkaistun pienmolekyyliagonistin Nag26 kohdalla.
Simulaatioiden vertailun pohjalta ehdotimme reseptorin sammuttamisen ja
aktivoimisen kannalta oleellisia vuorovaikutuksia.
Lisäksi tuotimme konformaatiostabiloituja oreksiinipeptideitä tutkiaksemme
peptidien bioaktiivista konformaatiota. Oreksiini-A:n suoran -heliksirakenteen
vakauttaminen, ainakin käyttämillämme menetelmillä, alentaa peptidien
voimakkuutta, muttei välttämättä tehokkuutta. Oletamme, että tuottamamme
muutokset ovat suoraan yhteensopimattomia oleellisten vuorovaikutusten kanssa tai
vaihtoehtoisesti vakautettu konformaatio on epäsopiva.
Kirjallisuuskatsaus käsittelee G-proteiinikytkentäisten reseptorien ja oreksiini-
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The orexinergic system comprises two G protein-coupled receptors OX1 and
OX2, and two endogenous peptide agonists, orexin-A and -B. These components are
mainly expressed within the central nervous system, where they participate in the
regulation of various systems, the main physiological function being the regulation
of the sleep–wake cycle. The activation of the system promotes alertness, whereas
decreased signaling causes sleepiness. The onset of narcolepsy is closely linked with
the destruction or malfunctioning of the orexinergic system.
At  the  beginning  of  the  research  presented  in  this  thesis,  the  amino  acid
sequences of the orexin receptors were available, but the crystal structures were still
to be solved. For the peptide ligands, the sequences and a collection of NMR-derived
3D structures in aqueous solution had been published, but it remained unclear
whether the bioactive conformation was among them. Studies had shown that the
C-terminus of the peptides was the key to biological activity and highlighted several
amino acids both in the receptors and in the peptides that were important. The
pharmaceutical industry had synthesized and reported a handful of well-characterized
small-molecular antagonists and a plethora of their analogs, linked with the race for
the orexin antagonist hypnotics. In contrast, the endogenous peptides and their
analogs were the only available agonists. A patent had been filed, reporting the first
small molecular agonist, but the patent or the application had not been published yet.
We set out to elucidate the binding mode of orexin peptides at their cognate
receptors, with the contingent aim to replicate the identified binding interactions with
a small molecule.
This dissertation comprises two peer-review publications and one manuscript
(Publications I–III). In Publication I, we describe two alternative binding mode
options  for  the  orexin-A peptide  at  the  OX1 receptor, achieved through homology
modeling and peptide docking. These binding modes are taken up in the Publication
III and subjected to extensive molecular dynamics simulations to address the stability
of the predicted interactions. Additionally, we simulated two small molecular ligands,
an agonist and antagonist to compare the differences in binding modes. The
simulations allowed us to propose a single, fine-tuned binding mode for orexin
peptides and to suggest determinants of agonist and antagonist binding.
In Publication II, we produced conformationally constrained orexin peptide
analogs with the aim of elucidating the bioactive conformation. A suitable constraint
Introduction
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might have also enabled the production of shorter orexin peptides that retained
bioactivity. Many of the conformationally constrained peptides were active, but to
our disappointment, with markedly decreased potency. However, this provided new
insight into the bioactive conformation and the peptide recognition within the
receptor binding site.
Review of the literature
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2 Review of the literature
2.1 G protein-coupled receptors
G protein-coupled receptors (GPCR) is the largest family of transmembrane
proteins with approximately 800 members in human, ~350 of them non-sensory
(smell, taste, or vision), recognizing a vast array of different ligands and even photons
through covalently bound chromophore “ligands”.1 They reside at cell membranes,
facilitating signal transduction across membranes. GPCRs are among the most
successful drug targets. Approximately one third of all approved drugs act on a
GPCR, and GPCRs constitute 12% of the protein targets for the approved drugs.2,3
Similar numbers are seen with molecules in clinical trials.
2.1.1 Classification
There  are  two  main  classification  schemes  for  GPCRs,  which  overlap  to  a
significant  degree.  The first  wide-spread system was the A–F classification,  which
was based on sequence and functional similarities.4,5 The  classes  were  A  for
rhodopsin-like and olfactory/taste receptors, B for secretin receptors, C for glutamate
receptors, D for fungal mating pheromone receptors, E for cyclic AMP receptors and
F for frizzled/smoothened receptors. Classes D and E are not found in vertebrates. A
more recent GRAFS classification1 defines five groups of human GPCRs: glutamate
(G), rhodopsin-like (R), adhesion (A), frizzled/taste2 (F) and secretin (S). Of these,
rhodopsin-like group is by far the largest, comprising approximately 700 members,
including the estimated 460 olfactory receptors. The rhodopsin-like receptors are
subdivided into branches , , , and . Orexin receptors belong to the -branch, along
with 33 other peptide-binding receptors.
2.1.2 Structure and function
GPCRs share a common fold, consisting of seven transmembrane helices
(TMs 1–7) connected by three extracellular and three intracellular loops, an
extracellular N-terminus and an intracellular C-terminus (Figure 1).6 The helices pack
into a bundle with a crevice between the extracellular ends of the TMs 2–7. This
crevice is the most common binding site for ligands in the rhodopsin-like group.7
Small molecular ligands often penetrate deep into the receptor, well within the cell
membrane. For large ligands such as peptides, the extracellular loops (ECL1–3) also
participate in the ligand binding. Some GPCRs, from groups other than the
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rhodopsin-like, are activated by interactions formed by the N-terminus alone. In these
cases, the ligand might be a protein of the extracellular matrix, for example.
In this thesis, I consider only the rhodopsin-like GPCRs. While there are many
similarities in function and signaling between the groups, many details in the
following chapters might not be true for the other subfamilies.
Figure 1. The conserved GPCR fold, illustrated with the OX1 structure 4ZJ88. The
horizontal lines show the approximate membrane location, suvorexant in orange
highlights the canonical small-molecule binding pocket, while an overlaid
endothelin9 (in green, transparent for clarity) shows that peptide binding often
includes also the extracellular domain.
Review of the literature
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2.1.3 GPCR activation
Long before the discovery of GPCRs, an abstract “receptor” was suggested to
bind acetylcholine at the neuromuscular junction, resulting in a conformational
change from an inactive receptor to an active one.10 Few decades later, and after the
discovery of GPCRs, this view was updated to a so-called two-state model, which
states that the active and inactive conformations of the receptor are in equilibrium in
the absence of ligands.11 Ligands could prefer binding to a specific state (agonist to
active and inverse-agonists to inactive) and shift the equilibrium through
stabilization, or bind without preference or effect on the equilibrium (antagonist).
This model had the advantage of explaining the basal activity of some receptors.
Parallel, it was observed that an unidentified, guanosine-related membrane
component X took part in the ligand–receptor interaction.12 The coined ternary
complex model described a low-affinity ligand–receptor interaction followed by the
X component binding, and a high-affinity ligand binding to a precoupled receptor–X
complex. The ternary complex of ligand, receptor and the component X could bind a
guanosine nucleotide, freeing the X component to activate downstream effectors. The
component X was identified as the G protein by the research group of A. Gilman,13
earning him a shared Nobel Prize in 1994. The ternary complex model was later
updated with the finding that the formation of the ternary complex was separable
from the G protein activation, and that the receptor needs to transition from an
inactive state R to an active state R* in order for the guanosine to bind.14
 The  Figure  2  shows  a  simplified  view  of  the  GPCR  activation  cycle.  The
important steps are ligand binding, G protein binding and receptor activation (R–R*).
It remains unclear, which binds first, the ligand or the G protein, or if both are
biologically relevant options. Receptor activation requires the bound G protein, but
the ligand presence is not necessary, at least not in all receptors.
Further studies have unveiled additional conformational states and elucidated
the exchanges between them.15–17 The current understanding is that unliganded
GPCRs exist in an equilibrium of states, most of them different inactive states, but
some also active, which mirrors the basal activity of some GPCRs. An antagonist
binds  all  the  states  with  little  preference  and  its  binding  should  not  disturb  this
equilibration. An inverse agonist prefers to bind to the inactive conformational states,
and the binding-induced stabilization shifts the equilibrium towards the inactive
receptor. Vice versa, an agonist shifts the equilibrium towards the pool of activated
conformations by preferentially binding the active states and stabilizing them. It is
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also possible for the ligands to bind “unfavorable” conformational states and induce
a transformation into their preferred state. However, no ligand is likely to impose the
receptor to adapt a single, rigid conformation, as that would be highly unfavorable in
terms of entropy. The identification of multiple states illustrates the receptor
activation pathway, and has helped in explaining the observation that certain ligands
can selectively induce only one pathway through a receptor that couples to multiple
pathways. This mechanism, which lies outside the scope of this thesis, is called biased
agonism.
2.1.4 Downstream signaling
As the name G protein-coupled receptor suggests, the G proteins have been
traditionally considered the main effector protein, the secondary messenger, of
GPCRs. The G protein consists of three domains, namely , , and .18 The -subunit
hosts a binding site for guanine nucleotides and GTPase activity. While the -subunit
joins and leaves the complex during the signaling cycle, the - and -subunits form
an inseparable dimer. There are at least 20 different -subtypes, falling into four
Figure 2. The functional cycle of  a  GPCR.  Pink:  Receptor  in  the inactive
conformation. Green: Receptor with the G protein binding site open. Orange, light
blue and blue: G , G  and G  subunits, respectively. Spheres: Ligand; R*: receptor
activation event, i.e. the receptor-induced GDP GTP transfer at the G protein.
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classes ( s, i/o, q, 12/13), each class with different effects on the downstream effector
proteins.19 For the -subunit, there are five subtypes and twelve for the -subunit, but
most combinations have similar downstream effects.
The complete G protein ( -trimer) with a bound guanosine diphosphate
(GDP) is able to bind a GPCR which has an open intracellular binding site, whether
ligand-binding-induced or spontaneously formed.18 The GPCR activation induces a
conformational change in the -subunit, which leads to GDP dissociation and the
binding of GTP (guanosine triphosphate) from the cytosol, which in turn leads to the
separation of the -subunit from the -dimer and both units leaving the GPCR.
While the receptor is free to activate the next G protein, the -subunit and the
-dimer pass on to activate further effector proteins. As the -subunit has GTPase
activity, the bound GTP is eventually cleaved to GDP, rendering the subunit inactive.
It then recruits the -dimer, cutting off its signaling too, and thus regenerating the
inactive GDP-bound G protein trimer for the next activation event.
In addition to G proteins, GPCRs bind also G protein-coupled receptor kinases
(GRKs) and arrestins.17 Initially, it was thought that these proteins merely served to
desensitize the GPCRs by GRK-mediated phosphorylation and subsequent arrestin
binding to block G protein/transducing binding20 (hence the name arrestin,21 as it was
observed to arrest the phosphodiesterase activity after rhodopsin activation).
However, it was shown that instead of merely blocking G protein signaling, arrestins
had downstream signaling of their own. For endogenous ligands, the traditional view
still holds (prolonged activity leads to arrestin-mediated desensitization), but not long
ago synthetic ligands have been found to provide continuous G protein activity
without arrestin-mediated desensitization,22 or in contrast only arrestin-mediated
signaling without the expected G protein signals.23 This is called biased signaling,
and the pharmacological application thereof are under intense research. Some GPCRs
have also been shown to form functional dimers.24 On top, many aspects of GPCR
signaling appear to be dependent on the expression system and the relative
abundances of different proteins. For example, biased signaling observed in vitro may
be driven by an abundance of a certain G protein subtype over another instead of a
biased agonist.
2.1.5 Determinants of activation
As described above, there are multiple inactive and active conformations (the
active conformation in this context refers to the conformation capable of G protein
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binding, not necessarily to the event that triggers nucleotide change within the
G protein). However, in the light of available GPCR crystal structures, there are
certain hallmarks to both (Figure 3).25,26 The most notable change to take place upon
GPCR activation is the outswing of the intracellular end of TM6 (Figure 3A), which
opens up the G protein binding site.27 This is of course not an isolated event, but
accompanied with distinct changes in the interhelical interactions at the intracellular
side and within the receptor core. Comparison of active and inactive structures has
highlighted a series of interactions present consistently only in either of the groups.26
Close interactions of the pairs 3x46–6x37, 1x53–7x53, 7x53–8x50, and 7x54–8x51
are seen in all inactive GPCRs, while these interactions are broken upon the opening
of the G protein binding site to give rise to interactions between 6x41–5x55 and
7x53–3x46 (Figure 3D–E). The conserved tyrosines at 7x53 and 5x58 are also
observed to reorganize to form a water-mediated interaction upon activation with
Arg3x50 hydrogen-bonding to Tyr5x58, which is related to the TM6 moving away and
TM5–TM7 distance diminishing (Figure 3B).25 In a subset of GPCRs, an “ionic lock”
between Arg3x50 and Glu6x30 stabilizes the inactive conformations and reorganizes to
form other interactions upon activation,28 but in orexin receptors an arginine is
present at the 6x30, and a suitable “replacement” acidic residue is not found within
the intracellular end of the TM6. Another feature linked with activation is the “core
triad” below the orthosteric binding site, formed by Pro5x50, Phe6x44 and a hydrophobic
residue at 3x40 (often isoleucine).29 The observation is that in the inactive state, the
hydrophobic residue at 3x40 lies in-between Pro5x50 and  Phe6x44 (Figure  3C).  An
activation-linked inward movement of the extracellular end of the TM5 would shift
or push the hydrophobic residue at 3x40 aside, thus allowing Phe6x44 to move closer
to TM5 and Pro5x50, facilitating the outward swing of the intracellular end of TM6.
The caveat here is that some crystallized receptors, such as the M2, feature a smaller
valine instead of the bulky isoleucine at 3x40, and fail to show marked differences
between the active and inactive core triad conformations, perhaps owing to less
restriction on the conformation of Phe6x44.29–31
The residue at site 6x48, most often Trp6x48, has been called the “toggle switch”
and thought to be linked with GPCR activation, as spectroscopic studies on rhodopsin
indicated that the Trp6x48 would change rotamers during activation.32,33 While this
hypothesis was undermined by the active rhodopsin, 2 and M2 crystal structures
showing inactive-like vertical conformation to Trp6x48 side chain,31,34,35 NTS1 has
been observed with a horizontal rotamer for the tryptophan side chain.36 In any case,
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the conserved aromatic residue at 6x48 might well play a role in the activation
cascade.
At the binding site level, the determinants of activation are more diverse, as
befits the vast diversity of GPCR ligands. It is suggested that a common activation
Figure 3. Inactive and active GPCR conformation, as seen with the 2-adrenoceptor
(PDB id: 2RH137 and 3SN627). A) View from TM6–7; B) Intracellular view; C) The
core triad (M2 receptor: PDB id: 3UON30 and 4MQS31); D–E) Common interactions
in active (D) and inactive (E) GPCR crystal structures. Green: Active; Orange:
Inactive.
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mechanism would be the contraction of the ligand binding cavity.25 Adrenoceptors,
for example, are thought to be activated by an inward motion of TM5 induced by the
ligand binding between TM5 and TMs 3 and 7, whereas the peptide-binding NTS1
shows an inward tilt of TMs 6 and 7 towards the ECL2.38
2.1.6 Ligand binding
2.1.6.1 Binding site
The GPCRs have a canonical orthosteric binding site within the extracellular
ends of the transmembrane helices. The ligand-binding depth for small molecules is
similar across receptors, but peptides bind at different depths.7 The Figure 4 displays
the binding depth for co-crystallized peptides, and the depth of our simulation-
derived peptide binding.
Figure 4. Ligand binding depth. A) Suvorexant in OX18; B) Orexin-A  after  MD
simulation; C) Endothelin-1 in ETB9; D) Apelin in apelin receptor39; E) an agonist
peptide DAMGO in μ receptor40; F) NT8–13 in NTS138; G) Modified angiotensin II in
AT241; H) an antagonist peptide PMX53 in C5a (complement) receptor42. The red
dashed line highlights the small-molecule binding site depth.
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2.1.6.2 The binding event in terms of thermodynamics
Ligand binding is a complex event. The ligand needs to diffuse into the
receptor binding site, which is sometimes assisted by the receptor extracellular
loops.43 Along the process, the ligand adopts a suitable conformation. Within the
extracellular fluid, the ligand is surrounded by water molecules, which it needs to
shed upon binding. The same goes for the binding site; it is not an empty cavity prior
ligand binding but filled with water, which needs to diffuse out of the cavity. Only
then can the ligand–receptor interactions take place.
Irreversible ligands aside, ligands bind through non-covalent interactions:
electrostatic attraction between opposite (partial) charges, hydrogen bonds,
-electron interactions and van der Waals interactions. While there is no actual
“hydrophobic interaction”, the term is useful in describing an observed effect of non-
polar moieties packing together. This rises from the fact that it is more favorable for
water to interact with polar groups (including other water molecules), and the packing
of hydrophobic groups reduces the surface area of the less favorable polar–non-polar
interface.
There are two main components in thermodynamics: entropy and enthalpy.
Entropy stands for the disorder of the system, and enthalpy describes the potential
energy of the system. Formation of chemical bonds decreases enthalpy, while the
breakage of bonds and different kinds of bond strains increase enthalpy. These are
often combined to calculate a change in the Gibbs free energy of binding with the
following equation: = . H stands for enthalpy, T for temperature and
S  for  entropy.  This  change  has  to  be  negative  in  order  for  an  event  to  take  place
spontaneously. The effects of various ligand-binding sub-events on these terms are
summarized in the Table 1.
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Often, ligand binding is though only in terms of binding interactions. However,
the conformational constraining of the ligand upon binding also plays a major role.
For example, it is beneficial to construct a rigid ligand, which is in a biologically
active conformation, instead of a flexible molecule that can adopt an active
conformation. Even if the active conformation is among the low-energy
conformations, the binding would result in decrease of conformational freedom and
thus in decrease of entropy. Solvation effects are also important. It is not enough for
the ligand to form favorable interactions with the binding site; the interactions need
to be superior to the interactions formed by water, both with the binding site and with
the ligand, otherwise the total enthalpic effect remains unfavorable.
2.2 Computational methods
The focus of the thesis research was on the use of computational tools to predict
orexin peptide binding into orexin receptors. The chapters below will offer a peak
into the toolbox and review the scientific discoveries others have reached with similar
methods.
2.2.1 Molecular mechanics and force field
Molecular mechanics (MM) stands for the modeling principle where classical
mechanics are used to mathematically model a molecular system. Generally, atoms
are treated as balls with a fixed radius, mass, and charge. Bonds and three-atom angles
are modeled as springs, or harmonic potentials, and bond rotation is expressed in
terms of a periodic function with multiple minima. Short-range non-bonded
interactions are usually calculated in a combination of Lennard-Jones potential44 and
Coulomb interaction, while long-range electrostatic interactions are often treated with
Particle-mesh Ewald (PME) method.45
Force field stands for a collection of mathematical functions and numerical
parameters that can be used to perform MM calculations. These include the atom radii
and partial charges, the ideal bond lengths and angles along with the spring constants,
and the form and parameters for the bond rotation.
Using MM with its assumptions is a trade-off between accuracy and efficiency.
Several problems rise from the fact that electrons are not considered: bonds cannot
form or break and charges on the atoms remain fixed. Also, a force field cannot treat
an atom or a molecule which it is not parametrized for. However, an alternative
method would be to resort to quantum mechanics (QM) calculations, which rely on
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calculation of the electron density. This of course provides superior accuracy, but the
cost on calculation time is such that QM is unfeasible for most anything larger than
a small molecule in a single conformation, whereas MM can deal with large systems
and timescales up to milliseconds. Also, bearing in mind the limitations on MM,
computational methods can often reach the limit of experimental error when one
sticks to well-parametrized systems.46
Molecular mechanics is used with both static and dynamic systems. For static
complexes, such as receptor modeling, small molecule conformation generation or
for docking purposes, MM can be used to calculate the potential energy of the system.
This can lead the selection of low-energy conformations for both small molecules
and proteins or the ranking of docking poses. In contrast to static systems, where MM
is used to calculate the energies of pre-generated systems, the dynamic use of MM
allows the relocation of particles to yield new conformations. This is useful in energy
minimization, for example, which is often linked with conformation generation, and
especially in molecular dynamics (MD) simulations.
2.2.2 Molecular dynamics simulations
Molecular dynamics simulation stands for the use of molecular mechanics to
derive  forces,  which  are  then  applied  to  the  system  of  atoms  using  classical
mechanics.  An  MD simulation  is  essentially  a  series  of  steps,  called  frames.  Each
frame consists of coordinates and speeds for all individual particles of the system.
From the coordinates and force-field-derived parameters, the simulation engine
calculates the forces acting on each atom. These forces are then used to calculate the
changes in the particle speeds, and each particle is allowed to move for a short period
of  time,  typically  in  the  ballpark  of  few  femtoseconds.  With  the  new  set  of
coordinates  and speeds,  the process is  repeated as  many times as  requested by the
user.
MD simulations enable the observation of a biological system in the atomic
level. The simulation allows for the examination of interatomic interactions over
time, as well as the large-scale movements within the system. Given long enough
simulation times, one could most likely observe ligand binding events, receptor
conformation changes, transporter protein fluctuations, ion channel function, or
protein–protein interactions.
Conventional  or  classical  MD  simulations  “seek”  the  lowest  energy
conformations. This is expected behavior, if one wishes to study, say, the stability of
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predicted interactions. However, if the goal is to observe transitions, this poses
problems, because even if both “ends” would be low-energy conformations, the
transition from one to another usually requires the system to adopt one or more high-
energy conformations along the way. While it is possible for the conventional MD
simulations to cross barriers of higher energy, it might require significantly longer
simulations due to the improbability of such events. As transitions are of paramount
importance in biology, several methods have been implemented.
Accelerated molecular dynamics introduces a “boost” potential, which
increases the energy of conformations that would fall below a set threshold. This
effectively makes deep energy-wells shallower, allowing for easier escape over the
neighboring energy barriers.47,48 Metadynamics, on the other hand, introduces similar
destabilizing potential component to simulation states that have already been
sampled.49 This requires the setup of geometrical criteria to differentiate between the
states.
2.2.2.1 MD simulations on GPCRs
GPCRs have been subjected to countless MD simulations to probe their ligand-
binding interactions and activation cascades.50 For example, massive classical
simulation efforts have elucidated the route and mechanism of small-molecule ligand
binding into adrenoceptors43 and the binding mechanism of allosteric modulators of
the M2 receptor.51 Through metadynamics, similar results have been obtained with a
fraction of the computational cost.52 For the geometrical criteria, the study used
simply the distance between a ligand and a residue at the bottom of the binding site
in a direction perpendicular to the membrane. In addition, the researchers placed an
inverted “cup” on top of the receptor, which applied a repulsive force to the ligand if
it was about to diffuse away from the vicinity of the receptor. These ligand-binding
simulations offer insight into the pathway of ligand entry and the events that take
place. In addition, they allow the estimation of binding affinity, which is often of
great interest to medicinal chemists.
As the GPCR activation takes place over millisecond timeframes53, the
transition from inactive to active has eluded even the longest unbiased simulations
up to date.54,55 However, the reverse event has been caught by conventional MD
simulations54. Relying on an assumption that the inactivation of the receptor takes the
same steps backwards as the receptor activation, this allowed for detailed suggestions
on the molecular mechanics within the activation cascade. Building on these
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simulations, an accelerated MD simulation was able to observe the activation event
of the M2 receptor.56
2.2.3 Homology modeling
Homology modeling refers to the methods, where a protein with a defined 3D
structure is taken as a template for the building of a model for the protein of interest
(“target”). The template and the target proteins should be close homologs for the
resulting model to be reliable, preferably from the same protein family. Additionally,
an ideal template structure should have high resolution, no crystallization-induced
defects and a high sequence identity for the target protein. The class A GPCRs do not
always display high sequence identity as the group is quite large and versatile, but
the  common  tertiary  fold  compensates  this  to  a  certain  degree,  at  least  for  the
transmembrane bundle.57–59 Successful homology modeling rests on two
cornerstones: sequence alignment and template selection. Sequence alignment stands
for the assignment of homologous amino acids between the template and the target;
together with the template they form a map for the modeling program where to place
each residue.
2.2.4 Peptide docking
Peptide docking is a challenging task due to the large number of atoms and the
inherent flexibility of the peptides.60,61 The prediction of very short peptides is
possible with the tools intended for small molecules,62 but longer peptides require
specialized software. The currently available peptide docking tools were recently
reviewed by Ciemny and co-workers.60 However, most peptide-docking software is
benchmarked with peptides of 15 amino acids or fewer, most of which are not
helical.63,64. Also buried binding sites have been problematic.65–67
A tempting, and often the only, option in docking longer peptides is to resort
to protein–protein docking software such as the Schrödinger PIPER68 or ZDOCK69.
Both perform rigid-body docking and score based on shape complementarity,
electrostatics and solvation effects.
2.3 Orexinergic system
The orexinergic system was discovered in 1998 by two independent research
groups. Early in January, an article in PNAS70 reported that an mRNA sequence
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expressed in the rat hypothalamus encodes a putative peptide precursor that could be
cleaved to yield two C-terminally amidated peptides, sharing sequence similarity
with each other and secretin. Conservation in mouse was shown, along with the
localization of the mRNA only in the hypothalamus within the brain, while the
predicted protein product was observed enclosed in vesicles within cells projecting
to various areas of the brain. The 28-amino-acid peptide was also found to be
neuroexcitatory in vitro, while the other peptide was not synthesized as the starting
position could not be deduced from the mRNA. By comparison to secretin, the group
suggested that the peptides could act through two (yet unidentified) GPCRs to
activate adenylyl cyclases, and based on the neuronal projections, the peptides could
serve as regulators of nutritional homeostasis. By the hypothalamic origin and the
resemblance to incretins, the group named the peptides hypocretins and the precursor
preprohypocretin.
Some six weeks later, an article in Cell71 outlined an extensive study aimed at
deorphanization of GPCRs by screening various tissue extracts against a panel of cell
lines expressing orphan GPCRs. The group identified a brain extract from rat which
produced a robust Ca2+-elevation through an orphan GPCR named HFGAN72 from
the human brain. As the response could be obliterated by protease pre-treatment, the
active component was likely a peptide. Three active components were purified and
identified. The main activity was assigned with a 33-amino-acid peptide with two
intramolecular disulfide bridges, an N-terminal pyroglutamyl residue, and C-terminal
amidation. An identical peptide was purified from a bovine hypothalamus extract.
The group termed the peptide orexin-A. Two other components were identified as a
linear, C-terminally amidated 28-amino-acid peptide and the N-terminally truncated
3–28 fragment thereof. The former was named orexin-B and the latter orexin-B3–28 as
it was unclear whether the shorter peptide was biologically relevant or an artifact
from the extraction and purification. Working backwards from orexin-A, the group
obtained the rat cDNA responsible for the peptide precursor prepro-orexin, and
subsequently the corresponding mouse and human genomic fragments, to learn that
orexin-A for these species was identical and orexin-B different by two amino acids
from the rodent orexin-B. The HFGAN72 receptor was confirmed as the receptor for
both orexin peptides, but orexin-A was 2–3-fold more potent than orexin-B. Through
a BLAST search of the GenBank database, the group identified a gene for another
receptor, which, when cloned and expressed, turned out to bind both orexin-A and -
B with high affinity. The deorphanized receptor was labeled as the OX1 receptor, and
the GenBank-derived was named the OX2 receptor.  Both  the  peptides  and  the
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receptors were predominantly expressed in the brain, which befit the hypothesis of
neuropeptides. The name orexin (the Greek word for appetite: , orexis) was
selected because the peptides increased food intake of rats, and the mRNA for the
precursor peptide was upregulated by fasting.
Quickly after their publication, the latter group lead by Masashi Yanagisawa,
noticed72 that their orexin peptides71 were identical to hypocretins70 discovered by the
group of J. Gregor Sutcliffe.
2.3.1 Signaling and physiological functions
The main downstream signaling pathway for orexin receptors appears to be the
Gq-mediated activation of phospholipase C, which produces IP3 and induces the
intake  and  release  of  Ca2+, resulting in the robust elevation of intracellular
Ca2+-concentration. However, depending on the cell line or tissue, also Gi/o- and
Gs-mediated regulation of adenylyl cyclase is observed. At the cellular level,
orexinergic signaling is neuroexcitatory through membrane depolarization.73 Orexin
receptors are mainly expressed within the CNS, where they participate in the
regulation of the sleep–wake cycle, energy homeostasis, stress and the reward
system.73 Orexin receptors are also found in several peripheral tissues, but the clinical
significance of these remains unclear, especially as the expression of orexin peptides
is limited to only a few sites throughout the body. Distribution by circulation has not
been shown to our knowledge, but pharmacokinetic parameters have been established
experimentally. Orexin-B degrades rapidly in blood,74 while orexin-A exhibits a half-
life of approximately 20–30 minutes,74–76 possibly due to peptidase protection offered
by the disulfide bridges. The complex details of orexin receptor downstream
signaling and cellular effects77 are outside the scope of this thesis.
2.3.2 Therapeutic potential
As the orexinergic systems participates in many physiological functions, there
are also multiple potential therapeutic areas. However, as the main physiological
function appears to be the modulation of sleep and alertness, the focus of the
pharmaceutical industry has been on the development of orexin antagonists as
hypnotics.78 In  addition  to  inducing  sleep,  the  orexinergic  system  could  also  be
targeted to reduce sleepiness, which would be key to successful narcolepsy treatment,
especially as malfunctions of the orexinergic system contribute significantly to the
onset of narcolepsy.79,80 Orexin receptors have also been located in certain cancer cell
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lines,  and  the  activation  of  these  receptors  directed  the  cells  to  apoptosis,  raising
interest as orexin receptors as potential cancer medication targets.81,82
2.3.3 Orexin receptors
The orexin receptors OX1 and  OX2 are  quite  similar  at  sequence  level  (full
length identity 64%, the TM bundle excluding ICL3 80% identical). Closest relatives
by sequence identity in human are the NPFF1 and NPFF2 receptors at 37% and 35%
identities for the TM bundle, respectively. The crystal structures for both orexin
receptors have been elucidated quite recently.8,83 The seven transmembrane helices
and the H8 at the C-terminus pack into the canonical GPCR fold, along with the short
loops ICL1, ECL1, ICL2 and ICL4. The ECL2 adopts a -hairpin fold similar to other
peptide-binding GPCRs. The loop is stabilized by the conserved disulfide bridge
between the ECL2 and the extracellular end of the TM3. In the first orexin receptor
crystal structure, 4S0V for the OX2,83 the conformation for the receptor N-terminus
could not be solved, but subsequent structures of both receptor subtypes8,84 have
shown a two-turn amphipathic -helix nine residues upstream of the TM1. In the OX1
structures, the N-terminal helix packs against the ELC2 hairpin, parallel to the
membrane plane, whereas the later OX2 structures show the helix facing away from
the receptor,  again parallel  to  the membrane (Figure 5).  Assays with orexin-A and
N-terminal deletion constructs of OX1 and  OX2 showed abolished binding and
activation of receptors,8 strongly suggesting a vital role for the N-terminus in orexin
peptide binding. The authors suggest that the amphipathic helix could recruit the
orexin peptide from the solution and guide it into the binding site formed by the
N-terminus, the ECL2 and the canonical GPCR binding pocket.
Figure 5. The extracellular domain of orexin receptors. A) OX2 (PDB id: 4S0V);
B) OX1 (PDB id: 4ZJ8); C) OX2 (PDB id: 5WQC)
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The orexin receptors have been subjected to site-directed mutagenesis (SDM)
with the intention to locate important residues for ligand binding and receptor
function.8,85–88 The mutations and their effects are listed in the Tables 2 and 3, and
illustrated in the Figure 6. Three mutations have a drastic effect on the receptor
function across a wide selection of ligands. The mutation of Tyr215/2235x39 to alanine
for example drastically lowers the orexin peptides’ binding affinity and potency, and
also abolishes antagonist binding.87,88 However, the receptor does express, and
localizes to the plasma membrane. Similar, but not quite as disruptive effect is seen
with alanine mutations of Trp206/21445x54 and Phe219/2275x43. Interestingly, all these
residues are aromatic, and closely situated. Trp45x54 and Tyr5x39 pack closely together
at the junction of ECL2 and TM5, facing the TM4 and not so much the binding site.
Phe5x43 is one helical turn below Tyr5x39, facing the TM3 as much as the binding site.
If  the packing of  these residues is  critical  for  the local  folding of  the binding site,
these mutations could cause a deformation which would explain the observed effects.
Orexin peptide binding or potency are also affected by mutations of 2x60,
45x51, 5x47, 6x48, 6x55, and to smaller extent by 3x32, 3x36, 7x34, 7x38, and 7x42.
Thr2x60, Asp45x51, and Asn6x55 offer polar interaction sites to the binding site, and it is
not surprising to find them contributing to the peptide-binding interactions. The
aromatic residues Tyr5x47 and Tyr6x48 are side-by-side at the bottom of the binding
cavity. As described above, the site 6x48 has been linked with the receptor activation
cascade. While Tyr5x47 faces the TM6 and not the binding cavity, it could be linked
to Tyr6x48 conformation or motions during the activation cascade, or to the large-scale
helical reorganization. Interestingly, alanine mutations of Tyr5x47 and Tyr6x48 also
produced a marked decrease in the efficacy of orexin-A, which supports the
hypothesis of an impaired activation cascade.
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Figure 6. Amino acids in the orexin receptors subjected to site-directed mutagenesis.
Coloring indicates the effect of an alanine mutation: Red, orange, and yellow for
decreasing deleterious effect, green for no effect.
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The antagonists differ slightly in their binding modes, at least in the light of
the effects on the site-directed mutagenesis.86–88 However,  most  are  affected  by
mutations of Gln3x32, Tyr6x48 and the aromatic residues in the TM7. An interesting site
for an alanine mutation is the Thr1353x33 in  OX2, as the corresponding wild-type
residue in OX1 is alanine. As expected, the mutation does not affect orexin-A, which
binds OX1 and OX2 with similar affinity, but reduces the affinity of orexin-B, which
favors the OX2. The mutation also impairs the binding and activity of OX2-specific
antagonists EMPA and JNJ-10397049. One would expect the OX1-specific
antagonist SB-674042 to gain affinity and potency, but interestingly a moderate
decrease in potency is observed, even though there is a small gain in affinity. The
reverse mutation A1273x33T in OX1 produces the expected loss of SB-674042 affinity
and potency, but here also almorexant affinity and potency are heavily decreased,
even though it is an antagonist for both receptors, and the mutation T1353x33A in the
OX2 had no effect on almorexant.
Mutations of 3x37, 5x40, 5x44, and 7x41 have no significant effect neither on
orexin peptide affinity or potency, nor affinity or potency of the tested small
molecular antagonists.
Chimeras  between  the  OX1 and  the  OX2 showed that ligand selectivity is
mostly conferred by the TM3.88,89 Two studies, employing different cut points, found
that either the region ECL1-TM3-ICL2-TM4 or the region TM2-ELC1-TM3 carries
the largest effect on the preference of the orexin-B for the OX2 receptor, as well as
the subtype selectivity for the antagonists. However, also combinatorial effects were
observed; for instance, the introduction of either the OX1 N-terminal  and TM1, or
OX1 TM7 and C-terminal into OX2 carries  no  effect  on  the  potency  of  an
OX1-specific antagonist, but a dual substitution of both induces a ten-fold increase in
potency.
2.3.4 Orexin peptides
There are two orexin peptides, orexin-A and orexin-B. Orexin-A is equipotent
towards both receptors.71,90,91 Orexin-B is as potent as orexin-A at OX2, but 10-fold
less  potent  in  OX1.71,90,92 As described above, orexin-A is a C-terminally amidated
33-amino-acid peptide with N-terminal pyroglutamate and two intracellular disulfide
bridges, and orexin-B is linear C-terminally amidated 28-amino-acid peptide (Figure
7A). The peptides are conserved across vertebrates and are also similar to each other
in terms of C-terminal sequence; 11 out of 15 amino acids are identical. The structure
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of both peptides in aqueous solution has been elucidated by NMR.93–95 Orexin-B
shows two helical segments, Leu7–Asn20 (helix I) and Ala22–Met28 (helix II), bent
90° 1.5 helical turns from the C-terminus (Figure 7B).94 In orexin-A, there are three
helical sections, Leu16–Ala23 (helix I), Asn25–Leu33 (helix II), and Asp5–Lys10
(helix III). The disulfide bridges stabilize a turn between the helices III and I (Figure
7). One study reports 30 conformation for orexin-A,93 falling into two categories; 5
conformations  are  straight  (Figure  7C),  joining  the  helices  I  and  II,  while  25
conformation are bent two helical turns from the C-terminus, in the opposite direction
than orexin-B (Figure 7E). Perhaps depending on the experimental conditions,
another study describes orexin-A in a 90°-bent conformation where the “hinge” is
similarly located, but the orientation of the N-terminus is oriented in another direction
by 90° (Figure 7D).95
Truncation studies on the orexin have shown that the conserved C-terminus of
the peptides is vital for biological activity,90 as suggested by the conservation of the
C-termini between the peptides. Even one-amino-acid C-terminal truncation yields
an inactive peptide, and the switch from amide the carboxyl has the same effect.90 In
contrast, N-terminal truncations are tolerable.90–92,96,97 Successive truncations display
reductions  in  potency,  until  peptides  shorter  than  19  amino  acids  fail  to  reach
maximal receptor activation. It is noteworthy that the entire N-terminal section with
the short helix and the disulfide-bridge-stabilized turn can be removed from orexin-A
while retaining the biological activity.
Figure 7. Orexin peptides. A) Sequences, disulfide bridges and locations for helices;
B–E) Solution NMR structures of Orexin-A (C–E) and Orexin-B (B).
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Within  the  helices  I  and  II  of  the  orexin  peptides,  hydrophobic  residues  are
grouped on one side, while the other is governed by polar residues (Figure 8B). This
gives the peptides a strong amphipathic nature. It has been postulated that this would
be a requirement for receptor interactions.93 The amphipathicity also hints towards
membrane interactions, as the membrane surface would provide a suitable water–
lipid interface for the orexin peptides. This has implications for ligand-binding
kinetics; a peptide “seeking” for a receptor could first settle on top of the membrane,
and diffuse along the two-dimensional space in the search for the receptor. This is
beneficial over the direct approach from the solvent, where there are more decrees of
freedom for the peptide movement and thus the binding would introduce a larger
decrease to entropy. The pre-coupling with the membrane would also reduce the
number of water molecules the peptide needs to shed upon entering the receptor.
Also, from the statistical point of view, in search of a membrane-bound receptor, it
makes sense to limit the search to the membrane.
Several mutation “scans” have been performed on the orexin peptides
(Tables 4 and 2006, Figure 8A).90–92,96,97 Alanine scan, where each residue in turn is
replaced  by  alanine,  is  the  most  common,  and  for  both  peptides,  there  are  two
individual studies reporting such scans. Orexin-A has been used as 14–3391 or 15–33
fragment,96 and orexin-B either in full92 or as 6–28 fragment.90 In addition, orexin-B
has been subjected to a full D-amino-acid scan92 and a proline scan,90 while only the
two C-terminal residues of orexin-A have been switched to D-amino acids.96 German
and co-workers97 have carried out site-directed mutagenesis on orexin-A17–33.
Apparently this shorter fragment is more sensitive to mutations, as the results are
incomparable to the body of other data. Especially the potency of orexin-A at OX2
was very low, and the effect of most mutations was significantly larger than in other
studies. Thus, these results are not included in the tables.
Taken together, the site-directed mutagenesis studies follow the trend set by
the truncation studies; the C-terminus is the most important section for activity
(Tables 4 and 2006). The most pronounced effect is tied with five C-terminal amino
acids. There, any mutation is highly detrimental to biological activity, except for L26
in orexin-B, which is tolerated by both receptors. On mutations T27A and M28A on
orexin-B, two studies disagree; one shows drastic drops for both mutations on both
receptor subtypes,92 whereas another reports only slight loss of potency for T27A at
OX2 and for M28A at both receptor subtypes.90 Apart from the C-terminus, Leu20/15
is vital for bioactivity. An alanine mutation results in moderate-to-large decrease in
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potency for the OX1, and in small-to-moderate decrease in OX2. A proline mutation
is also intolerable, which is not surprising as the residue is in the middle of a helical
segment. However, a D-Leu mutation here has no effect on the biological activity.
Except for Leu20/15 and Leu19/14, amino acids upstream of His26/21 appear to
tolerate alanine (or alanine to glycine) and D-amino-acid mutations quite well. Some
proline mutations are less tolerated.
Figure 8. The important amino acids and the amphipathic nature of orexin-A.
A) Amino acids color-coded on the tolerability of an alanine mutation. Red, orange,
and yellow for decreasing deleterious effect, green for no effect. B) Amino acids with
hydrophobic and hydrophilic side chains in brown and blue, respectively.
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Table 4. Mutations on
orexin-A.
Ala D-WT
Site WT OX1 OX2a OX1b
14 C = a =
15  R = a,b =
16 L = a / b =
17  Y = a,b =
18 E = a / b =
19  L  = a / b =
20 L a,b
21  H = a,b =
22 G = a,b =
23  A
24 G = a,b =
25  N = a,b =
26 H a / b =
27  A
28 A
29  G b
30 I b
31  L b
32 T b
33  L b
a, Ammoun et al. 2003
b, Darker et al. 2001
Table 5. Mutations on orexin-B
Ala / Gly for WT Ala D-WT / D-Ala for WT Gly Pro
Site WT OX1 OX2 OX1a OX2a OX1b OX2b
1 R = a = a = =
2  S = a = a = =
3 G = a = a = =
4  P = a = a = =
5 P = a = a = =
6  G = a,b = a,b = = =
7 L = a / b = a / b = = =
8  Q = a,b a / = b = = = =
9 G = a,b = a,b = = =
10  R a,b a,b =
11 L a,b = a,b
12  Q = a,b = a,b = = =
13 R = a / b = a,b =
14  L = a / b = a / b
15 L a / b a / b = =
16  Q = a,b = a,b
17 A a = a = = =
18  S a / = b a / = b =
19 G a / = b a / = b = = =
20  N a / = b a / = b = = =
21 H a / = b a / = b =
22  A = a  
23 A
24  G a,b a / b  
25 I a,b a,b
26  L a,b a,b =
27 T a,b a / b
28  M a / b a / b  
a, Asahi et al. 2003
b, Lang et al. 2004
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Through mutations, few OX2-selective peptides have been discovered.
Orexin-B with L11A and L15D-Leu  is  400-fold  more  potent  at  the  OX2 over the
OX192, while orexin-B10–28 is even more selective (at least 1750-fold)90. However,
[Ala11,D-Leu15]orexin-B is ten-fold more potent than orexin-B10–28. OX1 selectivity
appears to be harder to achieve, as the only peptide favoring the OX1 is the
orexin-A2–33 with unclosed disulfide bridges with a modest three-fold preference.90
Interestingly, German and co-workers97 found that L20D-Leu, which corresponds to
the L15D-Leu mutation in orexin-B, actually rescues some of the poor potency on
orexin-A17–33 towards OX2, while it is detrimental to potency for OX1.
2.3.4.1 Predictions on orexin peptide binding
In addition to the work presented here, to our knowledge only one group has
attempted to elucidate the binding mode for orexin peptides. Heifetz and colleagues85
built homology models of the orexin receptors with the D3 receptor as a template and
subjected the models to brief MD simulations. From the simulations, they picked a
pool of models for both subtypes. The article is not explicit on the matter, but from
the figures it appears that they elected to use orexin-A15–33 and orexin-B10–28 in lieu
of the full peptides. The fragments were docked into the pool of models through
ensemble docking, which allows the use of multiple targets. They suggest a docking
pose where the peptide C-terminus lies at the level of Tyr311/3176x48, H26 side chain
faces the TM4-side of the TM5, the peptide hinge is bent 90° and the middle helix of
the peptide points towards the TM7. Due to the use of D3 as a template, which has a
markedly shorter ECL2 loop than the orexin receptors, the models feature an ECL2
collapsed atop the binding site. As there were multiple peptide-binding receptor
structures available at the time of their study, all displaying the -hairpin ECL2, the
choice of D3 seems peculiar, and serves to highlight the importance of the modeling
template  selection.  Also,  while  collecting  several  target  models  from  an  MD
simulation could alleviate the potential problems linked with selecting a single model,
the simulation was equilibrated only for 200 ps, which is quite short. Either due to
short equilibration, or the use of the bent peptide conformations for docking, TM7 of
the OX1 model appears to feature a sharp bend, allowing the deep binding of the bent
peptide. The collapsed ELC2 might also force a deep binding mode and affect the
TM7. The authors do not discuss compatibility with full peptides, but it appears that
especially orexin-A, with the N-terminal bulk, would most likely be incompatible
with the presented binding mode.
Review of the literature
40
2.3.5 Small molecular ligands
Several small molecular ligands for orexin receptors have been developed. The
pharmaceutical industry has mainly been interested in antagonists, which have been
researched as hypnotics. The first, and this far only, antagonist suvorexant reached
the market in August 2014. Suvorexant has also been the molecule of choice for the
crystallographers, being the co-crystallized antagonist in the first crystal structures of
both orexin receptor subtypes, and therefore its binding interactions are well known.
The binding mode of suvorexant is discussed in detail later. Suvorexant is a dual
antagonist, binding both orexin receptor subtypes. Other dual antagonists have also
been developed and tested in clinical trials. There are also subtype-selective
antagonists for both orexin receptors, two of which have been crystallized with their
targeted receptors: EMPA with OX2 and SB-674042 with OX1.
Concerning agonists, the academic community has been more active than the
pharmaceutical industry. Most notably, the research group of Masashi Yanagisawa,
who were also the first to identify orexin receptors, has patented two series of orexin
receptor agonists98,99, and published a detailed description of the work leading to a
full OX2-agonist100. Our research group has produced and reported azulene-based
orexin receptor agonists (Additional publication V).
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3 Aims of the study
The main goal of the study was to understand the binding interactions of orexin
receptor ligands — foremost the natural peptides, but also synthetic small molecules,
and to deduce determinants for receptor activation. To this end, we carried out peptide
docking and extensive molecular dynamics simulations. To probe the bioactive
conformation of orexin peptides, we produced and tested conformationally
constrained orexin peptides.
The specific aims of the thesis were:
 To understand the molecular mechanism by which orexin peptides bind to
their cognate receptors, and how receptor activation is triggered.
(Publications I and III)
 To assess the bioactive conformation of the orexin peptides. (Publication II)
 To discover or design novel chemical compounds or (modified) peptides
that bind to and affect orexin receptor signaling. (Publication II and
additional publications IV and V)
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4 Materials and Methods
4.1 Numbering of GPCR residues
As GPCRs share a common overall fold, it is often reasonable to compare
homologous amino acid residues from different receptors. To facilitate this,
Ballesteros and Weinstein suggested a unified labeling convention more than two
decades ago.101 They proposed that since all transmembrane helices have conserved
regions, in each helix the most conserved amino acid would be denoted n.50, where
n stands for the number of the transmembrane helix from the N-terminus. Other
residues on the helix would be numbered consecutively using this midpoint as a
reference. This convention was widely accepted and remains still in active use.
However, the Ballosteros–Weinstein system considers only the protein primary
structure with predicted locations for the helices. The recent surge in resolved GPCR
3D structures has shown that, on closer inspection, the conformation is not identical
between receptors; the helices often show local constrictions and bulges as results of
amino acid deletions and insertions. Should the Ballosteros–Weinstein convention be
used, a homologous amino acid would receive a different number in two receptors if,
in either of them, there was an insertion or deletion between the amino acid in
question and the denoted central amino acid. To take this structural aspect into
account, the GPCRdb project has introduced an “updated” numbering scheme102,
where the central amino acids remain the same as in Ballosteros–Weinstein scheme,
but other amino acids are numbered based on their superposition on an ideal -helix.
In case of a constriction, the “missing” residue number is simply skipped, whereas in
the case of a bulge, the “extra” residue is given the number of the previous residue
appended with 1, e.g. 5x461 for the conserved bulge after the residue 5x46.
4.2 Homology models of the orexin receptors
As the orexin receptor crystal structures8,83 were solved during the research
project, we initially had to rely on homology models. Also, when the first crystal
structure was published, it was of OX2, while we were currently working with OX1,
and additionally, few amino acids were missing from the extracellular loops, so
homology modeling remained necessary throughout the research project.
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4.2.1 Template selection and sequence alignment
In publication I, we derived a sequence alignment for all 19 class A GPCRs*
that had a published 3D structure by superimposing the 3D structures and visually
inspecting which amino acids corresponded between the receptors. This served two
purposes; we could identify structurally conserved regions (both in terms of sequence
and secondary structure) among the receptors to guide the following sequence
alignment of OX1 to the sequences of the crystallized receptors, and we were able to
find locations where intrahelical amino acid insertions and deletions had taken place,
in case we would need to introduce such gaps in our alignment of OX1 and  the
template to be selected. We added the sequence of the OX1 based on the conserved
residues in each transmembrane helix. For the ECL2, we noticed that all published
structures of peptide-binding GPCRs (CXCR4, NTS1, and opioid μ, ,  and
NOP)38,103–107 featured  a  -hairpin  structure  between  TMs  4  and  5,  which  was
constrained above TM3 by the conserved disulfide bridge. We made sure that the
alignment of the OX1 to the crystallized receptors had no gaps within the expected
-strands.
For templates we chose the rat NTS138 and the CXCR4107. The NTS1 was the
first choice, as it lies in the -branch of the GPCR phylogenetic tree with the orexin
receptors.1 However, while NTS1 is also activated by a peptide ligand, neurotensin is
smaller than orexin peptides (13 amino acids in neurotensin versus 28 and 33 in
orexin peptides). As the NTS1 binding cavity is constricted by an inward tilt of the
extracellular end of the TM6, we had doubts whether the -helical orexin-A would
fit in. Therefore, we selected the CXCR4 as a secondary template, since the structure
shows  a  more  open  binding  cavity,  as  befits  a  receptor  whose  cognate  ligand  is  a
small protein. We also constructed a hybrid template by rotating the TM6 in the NTS1
*Class A GPCRs available at the time, and PDB identifiers thereof:
Rat NTS1 receptor, 4GRV38, Mouse μ receptor, 4DKL103,  receptor, 4DJH105,
Mouse  receptor, 4EJ4104, NOP receptor, 4EA3106, CXCR4, 3ODU107, 5-HT1B
receptor, 4IAR108, 5-HT2B receptor, 4IB4109, 2-adrenoceptor, 2RH137, Turkey 1-
adrenoceptor, 2VT4110, D3 receptor, 3PBL111, H1 receptor, 3RZE112, M2 receptor,
3UON30, Rat M3 receptor, 4DAJ113, A2A receptor, 3EML114, PAR1, 3VW7115, Squid
rhodopsin, 2Z73116, Bovine rhodopsin, 1U19117, S1P1 receptor, 3V2Y118
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structure to match the TM6 in the CXCR4 structure. Both template structures display
23.6% sequence identity to OX1, which would often be considered poor for homology
modeling. However, we were confident that the conservation of the overall fold
would compensate for this.
As  the  OX2 structure83 was published during the peer-review process of
Publication I, we included that in the study. The sequence alignment was of course
straightforward in this case, as the sequence identity of the TM bundles of the OX1
and OX2 is close to 80%, and nothing suggested that there would be any insertions or
deletions. In the Publication III, we used homology modeling to fill in the few missing
residues in the OX2 structure. Here, the sequence alignment was trivial, as we used
the OX2 as both target and template.
4.2.2 Model production and evaluation
For the Publication I, we produced ten OX1 models from each of the templates,
consisting of residues Tyr411x27–Gln2465x69 and Arg2916x28–Cys3758x60,  and  in  the
Publication III, 30 models of the OX2 comprising Pro501x28 Gln2545x69 and
Lys2946x25 Cys3818x60.  We  did  not  include  the  receptor  termini  or  the  ICL3,  as
suitable templates were not available at the time. The C-terminus and ICL3 would
also have had little impact in the ligand binding interactions, which was the main
focus. We used MODELLER119 9v8 and 9.14 with default settings for model
construction. In Publication I, we evaluated the models on the basis of ECL2 and
ECL3 conformations, as these were the main variable sections. We sought models
where the turn of the ECL2 hairpin resembled the crystallized peptide-binding
GPCRs, and the ECL3 did not constrict the binding site entry. From each template,
we selected one model. In the Publication III, we selected the model with the smallest
RMSD in comparison to the template structure 4S0V83.
4.3 Peptide docking
For all publications, we used the straight conformation of the orexin-A93. The
bent conformation is dominant in the published NMR structures, but our preliminary
docking suggested that it would not have been possible for the bent peptide to fully
reach the predicted binding site, unless the receptor structure deviated from the
crystallized peptide-binding GPCRs. However, modeling such receptor conformation
without a suitable template would not have been feasible.
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In Publication I, we decided to use the orexin-A16–33 fragment to avoid the
N-terminal disulfide-bridge-stabilized hook from “colliding” with the receptor
extracellular loops and thus limiting the sampling of the peptide C-terminus within
the binding cavity. In Publication III, we used the orexin-A2–33 in docking, since the
best poses from Publication I, which we sought to replicate, were achievable also for
the full-length peptide. However, we were forced to omit the first residue,
pyroglutamate, as the docking protocol did not include the required parameters. For
the simulation, we selected two high-scoring docking poses that represented the two
docking modes discussed in Publication I.
We used ZDOCK69 and RDOCK120 with  default  settings  to  carry  out  the
peptide docking and refining. These tools are initially built for protein–protein
docking, but they have found use also in peptide docking, since purpose-built peptide
docking software has been available mainly for short, non-helical peptides and
exposed binding sites. ZDOCK performs an exhaustive rigid-body docking and
performs pose clustering. We excluded the poses where the peptide C-terminus did
not interact with the receptor, or the peptide traversed between the transmembrane
helices into the membrane space. The rest of the poses were passed to RDOCK for
interaction optimization and re-scoring. We used Discovery Studio121 as an interface
for ZDOCK and RDOCK, and for the visual examination of the results.
4.4 Analysis of peptide location and orientation
For  publication  I,  we  sought  to  characterize  the  preferred  binding  area  and
space available for the orexin peptides. We approached this through an RMSD-based
clustering of the docking poses. For the pooled docking poses, we calculated a full
pairwise C -RMSD matrix with Matlab122. Then, we extracted modelwise clusters
with an algorithm123, where the pose with the largest number of close neighbors
(RMSD < 3 Å) — the cluster seed — is extracted from the pool with all its neighbors
to create the a cluster. This is repeated until no two poses are within the cutoff. Each
cluster was assigned the median RDOCK score of its members. For visualization of
the cluster locations, we used the cluster seeds as representative poses. To illuminate
the cluster packing and distribution, we produced a 2D representation of the RMSD
matrix via multidimensional scaling.
In  Publication  I,  we  also  assessed  the  solvent  accessible  surface  area  of  the
docked peptides with Naccess124, and measured their binding depth as a distance
along the z-axis (set to be perpendicular to the membrane plane) between the peptide
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L33 C  and the C -plane of Thr2235x461, Tyr3116x48 and Tyr3487x42. Direction of the
peptide H26 side chain, calculated as a vector in xy-plane from A28 C  to H26 C ,
served as a marker for the peptide rotational orientation.
4.5 Analysis of binding interactions
In Publication I, we considered any distance below 4 Å between non-hydrogen
atoms in the receptor and in the peptide as a contact between the respective amino
acid residues. For a group of similar docking poses, the interactions were collected
in heatmaps to identify frequent interactions, and a representative pose was selected,
in turn, by checking which of group member best reproduced the frequent
interactions. The analysis was implemented entirely in Matlab. From the
representative poses, we identified atom-to-atom interactions visually.
In  Publication  III,  we  carried  out  a  more  detailed  analysis  of  binding
interactions. We began with a similar distance-based mapping as in Publication I,
again with a 4 Å cutoff, using the Gromacs tool gmx mindist. This served to highlight
peptide side-chain orientations and hydrophobic contacts. In addition, we analyzed
both direct and water-mediated hydrogen bonding with the Gromacs tool gmx hbond
with default settings (donor–acceptor distance <3.5 Å, donor–hydrogen–acceptor
angle <30°). Direct hydrogen bonding was trivial as the tool is intended for the very
task, but for the water-mediated interactions, we devised an in-house Matlab-script.
The script functions as follows:
1. Search all hydrogen bonds between water and the receptor–ligand
complex (gmx hbond).
2. Discard water molecules that never have more than one hydrogen-
bonding partner at a time.
3. For each water molecule, identify the simulation frames where
multiple bonding takes place.
4. For each frame, identify the bonding partners and record the existence
of the bridged interaction at this frame.
5. Convert atom-to-atom bridges to residue-to-residue bridges.
In a molecular dynamics simulation, the water molecules rarely remain in the
same area through the simulation, but exchange rapidly with the bulk solvent.
Therefore, the script described above does not consider the bridging water molecule
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to be a part of the bridged interaction, but records only the amino acid heads of the
bridge.
We  treated  the  small  molecules  in  Publication  III  similarly,  but  instead  of
treating the whole molecule as one entity, we divided them into fragments for the
analysis. As far as the computer programs were concerned, these fragments were
treated just as amino acids were.
The entire simulation trajectory was analyzed for the direct interactions, while
frames at 3 ns intervals were used for the water-mediated interactions.
4.6 Molecular dynamics simulations
4.6.1 Overview
In Publication III, we produced a total of 36 μs of MD simulations on different
ligands in combination with the OX2 receptor in two different membrane
compositions. These are summarized in Table 6. For the system setup and analysis
we employed Gromacs 5.1125, and for the MD simulations Gromacs 4.6.7126.
Table 6. Molecular dynamics simulations





Orexin-A (TM5) POPC 3
Orexin-A (TM5) POPC 1
Orexin-A (TM7) POPC 3
Orexin-A (TM7) POPC 1
Apo POPC-CHOL (25%) 3
Suvorexant POPC-CHOL (25%) 3
Nag26 POPC-CHOL (25%) 3
Nag26 POPC-CHOL (25%) 1
Orexin-A (TM5) POPC-CHOL (25%) 3
Orexin-A (TM5) POPC-CHOL (25%) 1
Orexin-A (TM7) POPC-CHOL (25%) 3
Orexin-A (TM7) POPC-CHOL (25%) 1
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4.6.2 Force field parametrization and simulation protocol
For the protein and peptide, we selected the Amber99sb-ildn force field,127 as
it was the most recent Amber force field available. For the membrane lipids we used
the Splipids parameters,128 which were developed to be used in combination with
Amber force fields. As Amber does not contain parameters for the pyroglutamate (the
first residue in orexin-A), we created the connectivity manually, assigned regular
carbonyl atom types for the lactam carbonyl, and used partial charges from the Tinker
molecular modeling package.129
For suvorexant, we were able to produce bond parameters directly from
Antechamber130 with Gaussian-derived131 RESP charges. Nag26 parametrization was
not as straightforward. Antechamber provided a good template, but the parameters
for many of the “basic” bonds, such as the aromatic C–C bond, appeared to be slightly
different from regular Amber parameters. As Nag26 features mostly quite common
bonds, we were able to mainly use native Amber bond and angle parameters, and
resorted  to  OPLS/AA if  suitable  Amber  parameter  was  not  found.  This  mixing  is
possible as Amber and OPLS/AA are very similar. For dihedrals, we used mainly the
parameters from Antechamber, as they were mostly identical with native Amber or
differed only slightly. For sulfonamide, we substituted OPLS/AA parameters, as they
favored a 90° angle for the N-S-C-C torsion and 90°/270° angle for the X-N-S-X
torsion, which is supported by crystal structures.132 Also  for  the  torsions  of  the
aromatic amine, we used OPLS/AA parameters as Amber and Antechamber provided
none. For partial charges, we used AM1-BCC.133
We used periodic boundary conditions, and selected a hexagonal prism for the
simulation box, as it offers a 14.4% reduction in volume in respect to a rectangular
prism with similar periodic distance. Time-step was 2 fs, center-of-mass translation
was removed every 10 steps (solvent treated separately from the membrane with the
embedded components) and Verlet pair-list was updated every 20 steps. We used the
physiological temperature of 310 K (Nose–Hoover thermostat for solvent,
membrane, and protein complex separately), and pressure of 1 bar independently for
the membrane xy-plane and z-dimension (Parrinnello–Rahman). Short-range
interactions were cut off at 1 nm, dispersion correction applied for long range
pressure and energy and PME with default settings (cubic, 0.12 nm Fourier spacing)
for long-range electrostatics. LINCS constraints were used for all bonds.
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4.6.3 System setup, equilibration and production
The molecular dynamics simulation systems in Publication III comprised the
OX2 receptor model, an optional ligand, membrane model, solvent and ions. The
process of receptor modeling and peptide docking is described above.
4.6.3.1 Small molecule placement
Coordinates for suvorexant were extracted from the crystal structure 4S0V83
after  superimposition  to  the  OX2 receptor model. Nag26 was docked with Glide
induced-fit into the binding site of the crystal structure 4S0V, where suvorexant, but
not waters, had been deleted (Additional publication IV). Poses were then ranked by
their similarity to suvorexant binding. To maintain consistency, we did not use the
induced-fit-treated receptor from the docking, but again placed the Nag26 into the
OX2 model.
4.6.3.2 Membrane and system assembly
We constructed two hexagonal membranes for the simulations with Charmm-
GUI.134 In  the  pure  POPC  (1-Palmitoyl-2-oleoylphosphatidylcholine) membrane,
there were 150 lipids per leaflet, and in the mixed POPC-cholesterol membrane, we
used 126 POPC molecules and 42 cholesterol molecules per leaflet to yield 25%
cholesterol content. Both membranes were solvated into 12 nm high box of TIP3p
water.135
As cholesterol is shown to favor certain locations around GPCRs, we carried
out a coarse-grained (CG) simulation to decide initial cholesterol locations. In a CG
simulation, groups of atoms are replaced with single particles. Less particles means
fewer calculations per time frame, so CG simulations can achieve remarkably longer
time  scales.  The  OX2 receptor was embedded into three POPC-cholesterol
membranes (10, 25 and 50%) and simulated for 10 μs in each membrane. The
simulations revealed eight preferred locations for cholesterol molecules around the
receptor.  From  a  suitable  frame,  we  back-mapped  the  CG  receptor  and  the
surrounding lipids into an all-atom system.
To embed the receptor complex into the membrane, we used the Gromacs tool
membed. The tool shrinks the embeddable complex with a given factor (we used 10%
of the original size in the membrane plane, and original size along the z-axis),
superimposes the shrunk structure on the membrane, deletes the overlapping lipids,
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and gradually “inflates” the complex to its original size, pushing membrane lipids out
of the way. For the POPC membrane, we aimed at a symmetrical deletion of three
lipids per leaflet, but the slightly different center-of-mass at the peptide-bound
receptors caused the shrunk complex to be translated approximately 0.4 Å, resulting
in the deletion of an additional lipid from the intracellular leaflet. In the case of the
cholesterol-containing membrane, each receptor was first joined with the close lipids
extracted from the CG simulation. As this complex is larger and the close lipids were
not symmetrically distributed – five cholesterol molecules in the extracellular leaflet
and  three  on  the  inside,  along  with  15  POPC  in  both  leaflets,  and  the  target  is  a
multicomponent membrane, we ensured symmetrical outcome by pre-creating a
circular hole in a suitable place at the membrane by deleting 18 POPC molecules
from both leaflets, along with 6+4 cholesterol molecules. We then embedded the
receptor–lipid(–ligand) complex into the pre-generated hole with same settings as
above.
Finally, we neutralized the system charge and added 100 nmol/l of NaCl. The
final systems contained the receptor, optionally either orexin-A, suvorexant or
Nag26, 293–294 POPC or 246 POPC + 82 CHOL lipids, 25 100–25 200 water
molecules, 75 Na ions and 88–89 Cl ions (the orexin-A carries a positive charge).
4.6.3.3 Equilibration and production
The equilibration scheme is presented in Table 7. Each phase was simulated
for 10 ns. The equilibrated systems were then simulated for 3 μs. Additionally, we
started 1 μs replica simulations with the same files for the simulations with agonist
ligands (see Table 6).




1 Protein, ligand and cholesterol heavy atoms 1000
2 Protein and ligand heavy atoms 800
3 Protein and ligand heavy atoms 600
4 Protein and ligand heavy atoms 400
5 Protein and ligand heavy atoms 200
6 All C  and small molecule heavy atoms 200
7 Helical or peptide C , and small molecule heavy atoms 200
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For the equilibration and production simulations, we used the Sisu
supercomputer from the CSC – IT Center for Science. Each simulation was
distributed over 336 CPU cores, averaging approximately 130 ns/day, and thus
totaling a little over nine months of wall-clock calculation time and 255 years’ worth
of  CPU time.  The system setup and analysis  were carried out  on a  typical  desktop
computer.
4.6.4 Analysis
The analysis on the receptor and the ligand-binding interactions was conducted
with Gromacs tools125, VMD136 and Matlab122. For analysis, we centered the protein
complex and packed the membrane and the solvent into a hexagonal prism. Then, we
aligned the simulation frames based on the receptor  C  with such settings that  the
outcome was a smooth, continuous trajectory with no jumps. Most analysis was
carried out on these trajectories, with the following exception: due to limitations of
the analysis software and the physical RAM, the analysis concerning water, and the
preferred cholesterol locations were done with frames every 3 ns. In the analysis of
membrane thickness and area per lipid, we used unaligned coordinates, as the
receptor-based alignment tends to tilt the membrane and throw off the analysis.
We analyzed several aspects of the receptor and its interactions, as well as few
membrane properties. RMSD (root-mean-square deviation) was calculated both for
the  receptor  and  all  ligands.  An  RMSD  value  describes  the  similarity  of  two
conformations of the same structure. First, the comparable conformations are
superimposed,  then  a  square-root  of  the  sum  of  all  squared  pairwise  distances  is
calculated. For amino acids, we considered only the C , as it appeared to reflect the
conformational differences as well as all-atom or heavy atom calculations. For small
molecules, we took into account only heavy atoms. The alignment preceding the
calculation has a large effect on the value. Should a rigid ligand move around in the
receptor binding site, two outcomes are possible for the calculation: if the alignment
is based on the receptor, RMSD for the ligand atoms reflects the ligand motions, but
if  the  alignment  considers  only  the  ligand,  RMSD  would  be  close  to  zero,  as  the
ligand conformation remains close to the initial conformation. Thus, we produced
two RMSD values for the ligands: “external” RMSD stands for receptor-based
alignment and therefore describes the stability of ligand position, rotation and
conformation, and “internal” for the ligand-only alignment, which describes the
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conformational stability. For the receptor and orexin-A, we also calculated RMSF
root-mean-square fluctuation), which highlights the most mobile regions.
The analysis of ligand-binding interactions is described above. As the
interactions between receptor residues are also of interest, we used the same methods
to map receptor–receptor hydrogen bonds and water-mediated interactions. At the
“core triad” area, we also followed the distance and angle of the residues Val1423x40,
Pro2355x50 and Phe3136x44, and close to the G protein binding site, the interaction
distances Leu3106x41–Val2405x55 and Tyr3647x53–Ile1483x46,  which are conserved in
the activated GPCRs structures, and the distances Ile1483x46–Leu3066x37, Val751x53–
Tyr3647x53, Tyr3647x53–Phe3718x50 and Asn3657x54–Arg3728x51 conserved in the
inactive GPCRs. In addition, we monitored the salt bridges observed in the orexin
receptor crystal structures, namely Asp21145x51–Arg3286x59, Glu21245x52–His2245x40,
Arg3397x27–Glu1182x67, and Asp1152x64–His3507x38.
To estimate stable locations for water cholesterol molecules through the
simulations, we used the VMD tool Volmap with default settings.
 For the membrane, we calculated the area per lipid and membrane thickness
with GridMAT-MD137. As the tool assumes a rectangular box, we dealt with the edge-
problems by surrounding the simulation box with periodic images in the xy-plane,
and considered only the lipids in the “central” image for the analysis. As an estimate
for  the  membrane  thickness,  we  calculated  an  area-weighted  mean  of  the  P–P
distance  for  the  POPC  headgroups.  The  order  parameters  for  the  POPC  tails  we
calculated with gmx order, treating the double bond as described by Pluhackova et
al.138
4.7 Design of stapled peptides
In Publication II, we report a series of conformationally constrained peptides,
where a hydrocarbon linker is placed between two amino acids one helical turn apart
to force an -helical conformation. This process is called stapling.139 For the ease of
synthesis, we used orexin-A15–33 instead of the full peptide. The usage of a truncated
peptide might also allow us to observe if we could “rescue” some of the potency lost
with the truncation.
As our goal was to stabilize the straight -helical conformation of orexin-A,
our initial stapling location was the pair of alanine residues A23 and A27 (Figure 9).
A staple here spans the flexible linker between the C-terminal and central helix and
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should “lock” the straight helix, as well as provide overall stability to the helix. We
also  placed  staples  at  A27–L31  close  to  the  C-terminus,  and  at  L19–A23  at  the
N-terminus of the fragment we used. A staple near the end of a helix might provide
stability by stopping the “fraying” of the helix. The three positions all reside at the
hydrophobic face of the orexin peptide, which is suitable for a hydrophobic staple.
However, we decided to include a control position on the reverse side of the peptide,
which is predominantly polar. For this, we selected the site N25–G29.
Figure 9. Peptide stapling sites on the orexin-A15–33. A) Schematic of the stapling
sites. B–F) Comparison of modifications to wild-type side chains in terms of volume.
E  shows  the  Aib-variant, others the canonical eight-atom staple. The C-terminus
faces down, the flexible hinge is in gray, the wild-type side chains and their volume
in orange sticks and mesh, the modifications in white sticks and white volumes.
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The  peptides  were  assayed  for  their  ability  to  increase  intracellular
Ca2+-concentration via the orexin receptors, and also for their ability to block the
Ca2+-elevation induced by sub-EC50 concentrations of orexin-A.
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5 Results and Discussion
5.1 Orexin peptide binding
We approached orexin peptide binding through homology modeling of the
OX1 receptor, using mainly the rat NTS1 and human CXCR4 as templates, until the
crystal structure of the OX2 was released, at which point we adopted it as the docking
target and the template for OX1 modeling. For the ligand, we opted to use orexin-A,
first as the orexin-A15–33 fragment, then as full-length peptide. For the conformation,
we selected the straight -helical conformation of the orexin-A, as it seemed
improbable that the bent conformations shown by the NMR structures would
penetrate deep enough to interact with residues such as the Tyr311/3176x48,
Val130/1383x36, and Tyr224/2325x47. The validity of this hypothesis for the bioactive
conformation is discussed in detail below (5.2.2). However, as we have concentrated
our binding interaction analysis efforts at the peptide C-terminus, the results should




In the Publication I, we initially constructed three OX1 models based on three
template structures: NTS1, CXCR4, and a hybrid between the two, NTS1 helices and
side chains but with CXCR4-sized binding site. During peer review, the crystal
structure of OX2 was released, so the final article mainly considered the NTS1-based
model in addition to an OX2-based model, while the two other models were demoted
to “secondary models”. The NTS1-based model was quite accurate in terms of overall
fold; extracellular ends of the TMs 5 and 6 lean slightly inwards and the ECL3 and
the top of ECL2 differ in comparison to the OX2 crystal structure. At side-chain level,
there were multiple differences in rotamers, most notably Gln1263x32, His2165x40,
Tyr3377x31, Phe3407x34 and His3447x38.
5.1.1.2 Docking
We used orexin-A15–33 instead of the full peptide. The docking protocol treated
both ligand and peptide as rigid bodies, and we anticipated that possible collisions of
the peptide N-terminal hook into the receptor extracellular loops would restrict the
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mapping of the C-terminus, which was our main interest. In reality, the receptor loops
and the peptide N-terminus would be flexible and would thus allow C-terminal
docking poses that the rigid-body-docking would miss.
Either  due to the differences in the TMs 5 and 6 of  the models,  or  the side-
chain rotamers, the two models (OX2-  and  NTS1-based) produced and favored
differing pools of docking poses. The docking of orexin-A15–33 into the OX2-based
model produced a tight bouquet of docking poses, where the high-scoring poses were
dominantly upright or leaned slightly towards the TM5. In contrast, the NTS1-based
model produced a fan-shaped pool of docking poses, most likely because of the
narrower binding cavity due to the inward tilt of the TM6. The top-scoring clusters
showed a similar fan-like distribution, but the top-scoring individual poses were again
upright in the middle of the binding site. In both models, a good docking score was
tied to deep binding, but in reverse, deep binding did not guarantee a good score.
An examination of the high-scoring individual poses from both models
revealed that there were two main clusters of docking poses, separated by a rotation
of ~100° around the helical axis. We figured the reason for this division was that the
orexin-A  C-terminus  has  two  bulky  residues,  His26  and  Ile30,  facing  the  same
direction, and there are limited pockets available at the binding site large enough to
house this bulk. We selected the His26 side chain direction as a rotational marker and
noticed that it faced the TM5 in one of the main clusters and the TM7 in the other.
Therefore, we termed the two clusters TM5 and TM7 binding mode, accordingly.
Both models produced high-scoring poses with both binding modes, but the
OX2-based model favored the TM7 binding mode over the TM5 binding mode,
whereas in the NTS1-based model, the preference was reversed. Within the binding
mode clusters, there are also small differences in peptide tilting. In the TM5 binding
mode  cluster,  the  NTS1-based model shows one bundle of poses that lean slightly
towards the TM5 and another bundle, where the peptide is slightly deeper and
upright, whereas all poses from the OX2-based model share the position of the latter
group. In the TM7 binding mode cluster, both models produce only one bundle of
poses each, both leaning slightly towards the TM1, with the poses from the
OX2-based model a bit deeper.
We mapped common interaction patterns for both clusters and compared them
to the list of receptor amino acids that have been highlighted by SDM studies, and
also assessed the complementarity of hydrophobic and hydrophilic regions between
the peptide and the receptor model. On these accounts, both binding modes had
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merits, and as both binding modes appeared also to be compatible with full-length
orexin-A, we reported both binding modes as equal alternatives. For detailed
descriptions, see Publication I.
5.1.2 Molecular dynamics simulations on bound orexin-A
In Publication III, we set out to assess the stability of the binding modes
identified in the Publication I. As the binding modes had turned out to be compatible
with the full-length peptides, we begun by docking the orexin-A peptide into an
OX2-receptor model, only this time as a full-length peptide. From the resulting poses,
we selected two high-scoring poses that were close matches to the previously reported
binding modes. As there were sub-groups within the TM5 binding mode cluster in
the Publication I, we used the poses derived from the OX2-based model as references
when selecting the full-length docking pose (Figure 10). The bound peptides were
then simulated in two different membrane environments for a combined total of
16 μs.
The initial straight conformation of the orexin-A peptide did not appear to be
stable without the external support of the peptide N-terminus binding to the receptor
ELC2. The bending of the peptide, whether bound or free of the ECL2, dominated
the RMSD calculations, masking the events at the interesting C-terminus. Thus, we
analyzed only the peptide C-terminus.
In the TM5 binding mode, the peptide C-terminus was stable throughout the
simulations, but in the cholesterol-membrane simulations, it moves slightly in the
extracellular direction. In contrast, the binding of the peptide in the TM7 binding
Figure 10. Selection of TM5-mode
docking pose for the simulations. Two
“middle” poses from Publication I, one
for the NTS1-based model, the other for
the OX2-based model, shown in orange
and green, respectively. The selected
starting pose for simulations in gray.
Results and Discussion
58
mode was unstable in the simulations. Both the peptide conformation and the location
were less stable. Often, the hinge region would collapse towards the TM1, and in the
3 μs simulation in the cholesterol-containing membrane, also the helical structure of
the C-terminus melts within the binding site. Due to this significant difference in the
C-terminal  stability,  we  feel  that  the  TM5 binding  mode  is  likely  a  more  relevant
candidate for the orexin peptide binding mode. Therefore, the detailed binding
interactions are presented only for the TM5 binding mode. For further description of
the TM7 binding mode through the simulations, please refer to the Publication III.
However, as many peptides bind their GPCRs in an extended or partially extended
conformation (Figure 4), our preference for the stable -helix may later turn out to be
misplaced.
As the starting conformation for the TM5-binding-mode simulation in
Publication III was selected to recreate the TM5 binding mode from the Publication
I,  and  the  peptide  C-terminus  remained  stable  through  the  simulations,  it  is  not
surprising that the pattern of binding interactions is similar between the two studies.
However, the simulation had more freedom in the movement of amino acids and in
the optimization of interactions than the rigid-body docking. Also, the docking
protocol treats solvent implicitly, whereas the simulation featured an all-atom
solvent, allowing for the identification of water-mediated interactions. The binding
interactions observed with the TM5 binding mode simulation are presented in the
Table 8 and Figure 11.
Figure 11. The TM5 binding mode. A) Overview of the binding pose. Part of the TM6
and the ECL3 are transparent for clarity. B) Hydrogen-bonding between the peptide
and the binding site is often mediated by water.
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Table 8. The binding interactions in the TM5 binding mode.
Residue Interactions
Asn25 Tyr7x31 (Often H-bond between side chains, sometimes also to Asn25
main-chain carbonyl.) Direct or water-mediated H-bonding with Asp2x62
and/or Glu2x67. One simulation maintains an interaction from the starting
conformation: H-  bond from Asn25 NH2 to Phe7x34
His26 Packing or H-bonding with ECL2 (Asp45x51 and Glu45x52) or ECL3
(Lys6x58 and Phe7x34). Cholesterol-membrane simulations show local
tightening of the helix, relocating the His26.
Ala27 Faces ECL1 but makes no defined interactions.
Ala28 In a pocket lined by His7x38, Thr2x60, Val2x63, and the aliphatic chain of
Asp2x64.
Gly29 Allows for close packing of His7x38 against the side of the peptide and
the A28–G29 amide bond.
Ile30 Between Met4x65 and Pro3x29. Main-chain carbonyl binds with the
C-terminal amide.
Leu31 Side chain in a pocket lined by Pro3x29, Ile3x28, Trp23x50, and Thr/Ser2x60.
Main-chain carbonyl H-bound with Gln3x32.
Thr32 Side chain: Tyr7x42, Val7x41, His7x38, Ile6x51, and Thr2x60. H-bond mostly to
Ala28 main-chain carbonyl, unless His7x38 flips upward, exposing a
suitable binding partner (in cholesterol-membrane simulations).
Main-chain carbonyl: a single water mediates interactions to Gln3x32
side-chain carbonyl and Tyr6x48 hydroxyl.
Leu33 Side chain in a pocket lined by Ile6x51, Asn6x55 and Phe5x43.
Main-chain carbonyl interacts transiently with water beneath the peptide.
NH2 Mostly binds to Gly29 or Ile30 main-chain carbonyls, transient
interactions with water beneath the peptide.
A keen eye will notice that the interactions listed in the Table 8 are somewhat
different from the Table 1 and Figure 9 in Publication I. This is mostly because the
interactions in the Publication I were defined from a single representative pose. As
the TM5 binding mode was more popular among the docking poses from the NTS1-
based model, the representative pose rose within those poses. Further, the
representative pose shows the slightly higher binding along with the TM5-facing tilt.
In contrast, the starting conformation for the simulation was selected to represent the
TM5 binding mode adopted by the docking poses from the OX2-based model, which
were deeper and upright. This reflects on Asn25 and His26, which are closer to TM5
in the interaction listing in the Publication I, and on some of the C-terminal residues,
which are not as deep in the Publication I. In hindsight, it would have been prudent
to select the representative pose for the TM5 binding mode among the deep-and-
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upright cluster, which was present in both models, instead of the NTS1-based-model-
specific TM5-leaning cluster.
5.2 Orexin peptide bioactive conformation
The NMR-derived 3D structures of the orexin peptides highlight the flexibility
of the peptide especially at the hinge region between the C-terminal helix and the
middle/N-terminal helix, some 1.5–2 helical turns from the C-terminus. For orexin-A,
three different hinge conformations have been reported, and orexin-B adopts a fourth.
It is likely, although not yet shown, that the orexin peptides would bind to their
receptors in a conformation similar to the conformations seen in the solution. This is
discussed further in 5.2.2.
5.2.1 Modified peptides
In Publication II, we produced conformationally stabilized variants of
orexin-A15–33 through helical stapling and aminoisobutyric acid (Aib) replacements
to probe the bioactive conformation (Figure 9). Our hypothesis was that the peptide
would bind in the straight -helical conformation, as that allowed for the docking of
the peptide deep enough to interact with residues shown to be important by the site-
directed mutagenesis. We selected four sites for modification in search of a site where
the helix-stabilizing modification would be compatible with the peptide–receptor
interactions. Three of the sites were on the hydrophobic side of the peptide, as the
hydrocarbon staple is hydrophobic, and one was on the hydrophilic side, mainly
intended as a negative control (Figure 9 for the staple placement, Figure 8 for the
hydrophobic/hydrophilic side). Initially, we introduced a “standard” -helix-
stabilizing eight-atom staple in each site, labelled “nA”, where n stands for the site.
Starting from the peptide C-terminus, 1A and 2A were (near) inactive up to a
concentration of 20 μM (Figure 12). 1A was extremely weak at OX1 and inactive at
OX2, while 2A was inactive at both subtypes. This was not surprising. Site 1 is at the
vital C-terminus and the staple replaces A27 and L31, which do not tolerate mutations
well (Tables 4 and 2006). The mutation L31A, or the corresponding L26A in
orexin-B, is destructive for the activity. The mutation L26D-Leu  in  orexin-B  is
intolerable, and a D-alanine mutation of A22 in orexin-B, corresponding to A27, also
results in a moderate drop in potency. Concerning site 2 (N25, G29), the mutation
N25A in orexin-A seems to be tolerable,  but  one study reports  a  moderate  drop in
potency for the corresponding mutation N20A for both receptors. The G29 and the
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corresponding G24 show moderate to large decreases in potency with alanine or
D-alanine substitutions. Put together, the site 2 seems to fulfil our expectations of a
negative control.
Peptides 3A and 4A were more potent but still showed marked drops in
potency with respect to orexin-A15–33. 4A reached full receptor activation with near
three orders of magnitude lower potency, and while 3A produced a robust response,
it did not reach response saturation within the tested concentration range (up to
20 μM). Assuming full efficacy, the decrease in potency for 3A would be three-to-
four orders of magnitude. In contrast to the sites 1 and 2, the amino acids at sites 3
and 3 (A23 & A27 and L19 & A23, respectively) should have tolerated the mutations
better. The effect of the mutations L19A (orexin-A) and L14A (orexin-B) varies
between no effect to moderate decrease in potency between studies and receptor
subtypes. There are no mutants for A23 and A27 in orexin-A, but the corresponding
S18 and A22 in orexin-B have been mutated. The S18 tolerated both alanine and
D-serine mutations with only a small decrease in potency. The A22G mutation is
tolerable, but a D-alanine mutation shows a moderate decrease in potency. However,
the loss of potency for the stapled peptides 3A and 4A was markedly greater than
expected based on the SDM data. There were three likely causes for the observations;
the staple-stabilized conformation was wrong per se, conformational flexibility is
required upon receptor binding, or the modifications were directly incompatible with
ligand–receptor interactions.
We approached the putative problem of a wrong conformation by synthesizing
a series of peptides (3B, 3C, 3D) with varying staples at site 3, which spans the hinge
region. We hoped that these peptides could adopt a more suitable conformation. Their
activity was, however, similar to 3A, so either the conformation was still wrong, or
the problem lay elsewhere. Next, we tested two linear peptides (1AL and 3DL), where




the unnatural stapling residues were present, but not cross-linked. The rationale was
to  differentiate  between  the  effects  of  the  amino  acid  replacement  and  the  cross-
linking. As these were slightly more potent than their ring-closed counterparts, it
indeed appears that the cross-linking is detrimental to potency. However, the linear
precursors were still far less potent than the “wild-type” orexin-A15–33. Therefore, the
modified residues themselves were the root of the problem.
The amino acids used for the stapling have an alkane side chain with a vinyl
group at the end, and an additional methyl group at the C . The chiral configuration
used in our study is S, i.e. corresponding to the L-amino acids. We sought to separate
the effects of side-chain modification and C -methylation by incorporating
-aminoisobutyric acid (Aib) at site 3 instead of the stapling residues (3EL). Aib is in
essence a C -methylated alanine, so it was an ideal replacement for A23 and A27 at
site 3. Aib is also helix-stabilizing, as the C -methylation limits the conformational
flexibility of the peptide. The compound 3EL was 5–12-fold more potent than the
linear 3DL,  and  the  most  potent  peptide  carrying  a  modification  at  site  3,  but  less
potent than 4A (3.5-fold in OX1 and 1.5-fold in OX2) and far inferior in comparison
to unmodified orexin-A15–33.
None of the modified ligands was able to block orexin-A-induced
Ca2+-elevation, which indicates that the modifications most likely impair the
peptides’ ability to bind to the orexin receptors, not only their ability to activate the
receptor. The purified quantities of the stapled peptides were not sufficient for proper
binding assays.
Given that the Aib-substitution introduces only two additional C -methyl
groups, and carries almost as large a potency decrease as the helical stapling, it seems
likely that the problem for all our modifications (at site 3 at least) lies with these two
methyl groups, which are also present in the amino acid used for stapling. The root
of the problem is likely either the stabilization of the helical conformation, which
might be incompatible with the binding site or the events of the peptide entering the
binding site, or the methyl groups directly blocking the peptide–receptor interactions
which should take place between the receptor and the peptide backbone, which is
exposed  upon  helical  bending.  A  joint  effect  is  also  possible,  where  it  is  not  the
methyl groups but the induced helical stabilization which blocks the interactions.
Assuming that the modifications we produced do stabilize the helical
conformation (in hindsight, we should have utilized circular dichroism spectroscopy
or NMR to verify the increased helicity, as successful stapling does not guarantee
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-helical conformation140), our peptides show that the orexin receptors can indeed be
activated by all-helical peptides with sub-micromolar concentrations (4A and 3EL).
However, it might also be that it is the portion of the peptide which is not all-helical,
despite the stabilization, which triggers the receptor activation.
5.2.2 Insights into the bioactive conformation
We  have  presumed  that  the  orexin  peptides  bind  to  their  receptors  in  a
conformation which is similar to those observed in aqueous solution by NMR. In
essence this means -helical conformation for the peptide C-terminus. There are few
solid reasons for this assumption. First, from the thermodynamics’ point of view, it
is beneficial for the ligand to prefer the bioactive conformation already in the solvent;
this way, the binding decreases entropy only by constricting the ligand position, not
so much the conformation. It would also reduce the likelihood of ligand binding, or
at least introduce a delay, if the peptide needed to cross an energy barrier to reach the
bioactive conformation or unfold upon binding. Secondly, truncation of orexin
peptides is tolerated down to 19 amino acids, whereas shorter peptides show drastic
loss in potency and efficacy. This coincides with the length of peptide which is
generally regarded necessary for the adoption of stable -helical fold, unless specific
stabilizing factors such as repeated charged residues are present.141–144 Also, as the
residues lost with these further truncations are not particularly important in the light
of the SDM data, it stands to reason to suggest that the reduction of potency would
be linked with decreasing helicity.
When considering the orexin peptide bioactive conformation, it is of course
prudent to take into account the conformation the orexin receptors. After all, a peptide
conformation can hardly be bioactive, if it does not correspond to the requirements
of  the  receptor  binding  site.  The  recent  crystal  structures  of  OX18 showed a short
amphipathic helix at the extracellular receptor N-terminus, close to the ECL2, parallel
to the membrane plane. Through mutagenesis, the authors show that the short helix
is instrumental in orexin-peptide-mediated receptor activation in both receptor
subtypes. If the N-terminal helix does indeed reside close to the ECL2, and not face
away of the receptor, as suggested by another study84, it would “cap” the binding site,
thus preventing the binding of a straight helical full-length orexin-A and explaining
why the peptide needs to bend at the hinge region. Although the orexin-A15–33 used
in the Publication II would fit underneath the N-terminal helix in the straight helical
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conformation, the straight helix would of course miss many of the interaction sites
that a bent peptide would find.
Our MD simulations (Publication III) did not include the newly discovered
N-terminal helix, and we began the simulations with the straight conformation of the
full-length orexin-A. Across the simulations, there were two main paths for the large-
scale conformation for the peptide. If the peptide N-terminal domain found (charge-
assisted) hydrogen-bonding partners from the receptor ECL2, the peptide remained
upright and maintained the straight conformation at the hinge region. However, if
such bonding did not occur, the peptide showed a tendency to bend more or less at
the direction of H26. In the TM5 binding mode, this means that the helix I in the
middle of the peptide and the N-terminal domain come to rest horizontally over the
binding site, atop the latter -strand and the extracellular end of the TM5. The
resulting binding mode and location is strikingly compatible with the location of the
receptor N-terminal helix (Figure 13B). The conformation of the peptide does not
closely represent any of the published NMR-structures for the orexin peptides (Figure
13C). The direction of the bend is similar to orexin-B, but the hinge is one helical
turn higher than in the orexin-B NMR-structure. Hinge location is identical to
orexin-A solution NMR-structures, but the direction of the bend is different to both
published bent conformations.
A synthesis of the available data suggests that the bioactive conformation for
the orexin peptides could be the bent conformation. Our modified peptides show that
stabilizing the peptide in the straight helical conformation is detrimental to
bioactivity, the NMR-data suggests that the peptide is more likely to be found in the
bent conformation, at least in solution, and the recently discovered N-terminal helix
caps the binding site in a way that discourages the binding of the straight helical
orexin peptides. Our simulations show that the straight conformation is likely not
stable without interactions between the peptide N-terminus and the receptor ECL2,
which in turn would be blocked by the receptor N-terminal helix. Further, in the light
of the receptor N-terminal helix, it is difficult to imagine where else the peptide
N-terminus (the N-terminal hook and the middle helix in orexin-A, or the N-terminal
helix in orexin-B) would lie than atop the ELC2, towards TM5. But what about the
hinge direction?
The solution NMR studies highlight the flexibility of the hinge, showing three
possible bending “modes” (Figure 13C). Our simulations show a fourth mode. A
crude manual docking of orexin-A as seen in solution93, not considering the
Results and Discussion
65
C-terminal interactions, would place the middle amphipathic helix atop the ECL2
with hydrophobic residues facing down towards the binding site and polar residues
facing up towards the receptor N-terminal helix (Figure 13A). The latter would bring
together polar residues from both parties, and at a first though, burying hydrophobic
residues between the peptide and the receptor would make sense. However, the
binding site is rimmed with polar amino acids in the ECL2 and ECL3, and this
binding pose would bring these in contact with the hydrophobic peptide residues,
which is hardly favorable. In contrast, our simulation-derived binding mode shows
the peptide middle helix in a rotational state which presents the polar amino acids
from the peptide towards the polar rim of the binding site, and hydrophobic peptide
amino acids towards the receptor N-terminal helix. This would bring hydrophobic
peptide residues together with the polar residues of the receptor N-terminus, again an
unfavorable interaction. However, the rotational state of the amphipathic N-terminal
Figure 13. Orexin-A conformation and compatibility with the receptor N-terminal
helix. A) Manual insertion of the orexin-A solution-NMR structure; B) Simulation-
derived orexin-A conformation; C) Comparison of orexin peptide conformations.
Green: Simulation-derived; Gray: Orexin-B (NMR); Blue: Straight conformation of




helix of the receptor is peculiar in the crystal structure; the hydrophobic residues face
away from the receptor, towards the solvent. As this might reflect the crystallization
conditions and packing instead of the biological conformation, we hypothesize that a
roll of ~180° would bring the hydrophobic residues from the receptor N-terminal
helix in contact with the hydrophobic face of the peptide helix, burying both from the
solvent, while the polar side of the receptor N-terminal helix would become exposed
the solvent.
On the other hand, and despite the evidence discussed above, the straight
-helical conformation might still turn out to be the bioactive conformation. As
mentioned, there are two alternative conformations for the receptor N-terminal
helix,8,84 and only one of them caps the binding site. The other displays the helix
facing away from the receptor. However, as mutations in the N-terminal helix impair
the peptide-induced receptor activation, it seems likely that the N-terminus would be
in contact with the helix. It is possible that the N-terminal conformation seen in the
crystal structures is relevant only for the small-molecule-bound receptor, and that the
receptor N-terminus might adopt a third conformation upon peptide-binding, which
would permit the binding of the straight -helical peptide. Concerning our modified
peptides, which were indisputably weaker than the corresponding wild-type peptide,
the reason might have been a direct incompatibility of the modifications with the
binding site, not the stabilized all-helical conformation.
5.3 Small molecular ligand binding
5.3.1 Antagonists
The crystallized antagonists suvorexant, EMPA, and SB-674042 share the
same binding location (Figure 14).8,83,84 SB-674042 and Suvorexant are similar
molecules, and they also adopt a similar, horse-shoe-like conformation. EMPA
differs chemically but also folds similarly and finds the same subpockets for binding
(Figure 14).
Concerning large-scale conformation, all molecules feature two sandwich-
packed aromatic groups. Suvorexant folds on a 1,4-substituted diazepane ring to
achieve this, and SB-674042 via 1,2-substituted pyrrolidine. These rings also overlap
in the middle of the binding site, facing Phe5x43 and  His5x40.  The  rings  are  next  to
Ala/Thr3x33. EMPA produces similar packing through a sulfonamide moiety, which
occupies a different space, while an N-ethyl group reaches the site occupied by the
Results and Discussion
67
N-heterocycles from other antagonists. Next to this “central” moiety, all antagonists
feature an amide carbonyl, pointing roughly in the directions of Asn6x55.  A
crystallographic water often links the carbonyl with His7x38.
The two closely packed aromatic moieties are chlorinated benzoxazole and
toluene in suvorexant, benzene-linked oxadiazole and methylated thiazole in
SB-674042, and toluene and methoxypyridine in EMPA. The former stacks next to
Pro3x29, occupying a pocket lined by Cys2x56, Ala2x59, Ser/Thr2x60, Val2x63, Trp23x50,
Ile3x28, and Gln3x32. The latter is positioned with His7x38, Val7x41 and Tyr7x42 in TM7,
and flanked by Gln3x32 and  the  other  aromatic  moiety  on  the  other  side.  A  third
Figure 14. Antagonist binding. A) Suvorexant in OX2. The OX1-binding is identical.
B) Suvorexant in OX2 after a 3 μs MD simulation; C) SB-674042 in OX1; D) EMPA
in OX2. As the viewpoints and selections of binding site amino acids macth, labels
are only shown in panel A. Thr5x461 is additionally shown in panels B and D, as it
serves as an anchor point for the water-binding network.
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aromatic group reaches towards the TM5, into the pocket lined by Tyr6x48, Val3x36,
Ile6x51 and Phe5x43. This aromatic moiety is a triazole in suvorexant, a fluorobenzene
in SB-674042, and pyridine in EMPA. The group might play a part in trapping few
water molecules between the TMs5 and 6.
Concerning the selectivity between the orexin receptor subtypes, there are two
sites of interest, 2x60 and 3x33, which were also highlighted by SDM studies.87,88
The OX1 has  Ser2x60 and Ala3x33,  while  OX2 has Thr2x60 and Thr3x33. SB-674042 is
likely OX1-selective because the pyrrolidine produces a steric bulk incompatible with
Thr3x33 in OX2, but the Ala3x33 in OX1 leaves enough space for the moiety. For EMPA,
there is not a single obvious reason for the selectivity. It might gain OX2 selectivity
by not reaching as close to TM2 and 2x60, where the OX2 has a larger amino acid
than the OX1; then again, suvorexant is closer to TM2 than EMPA and binds equally
to both subtypes. Same goes for the turn structure: SB-674042 protrudes close to
TM3 and Ala3x33, EMPA resides further from the Thr3x33, thanks to the sulfonamide-
based turn structure, but suvorexant shows that a distance much shorter than EMPA´s
is still acceptable. It would be tempting to account the sulfonamide carbonyls for the
selectivity, especially with the Thr3x33 close by for hydrogen-bonding. However, the
crystal structures show the Thr3x33 hydroxyl facing the other way and hydrogen-
bonding intrahelically. Rotamer change would bring the hydroxyl closer, but the
distance and geometry would remain unfavorable. Perhaps a water-mediated
interaction takes place, or the Thr3x33 hydroxyl plays a role in repositioning Gln3x32 to
interact with the sulfonamide carbonyls. However, the comparison to suvorexant
might be misleading. Although suvorexant is a dual antagonist, it is more potent than
EMPA towards  the  OX2;  the  OX2-selectivity  of  EMPA arises  more  from the  poor
OX1-binding than exceptional OX2-binding.  The case might  simply be that  EMPA
keeps its distance from both 2x60 and 3x33, and the larger residues in the OX2 still
reach to interact with EMPA to a degree, whereas the smaller residues of the OX1 do
not.
In the Publication III, we simulated suvorexant bound with the OX2. We began
the simulation with the small molecule location and interactions from the crystal




5.3.1.1 Mechanism of antagonism
To begin with, it is important to notice that an antagonist merely needs to block
agonist binding, and as such, there cannot be an actual (conserved) mechanism of
antagonism.  However,  there  are  few  sites  of  interest  in  the  binding  site,  that  all
crystallized orexin receptor antagonists seem to share.
All orexin receptor crystal structures have been obtained with a bound
antagonist, and all show hydrogen-bonding link of Gln3x32–Tyr7x42. Consistently, our
simulations with suvorexant maintains this link, while none of the other simulations
do so, at least not to the same extent. We hypothesize that this interaction could be a
hallmark for an inactive state of orexin receptors.
5.3.2 Agonist Nag26
We simulated the Nag26 agonist in four simulations for a total of 8 μs (Table
6). Unlike the antagonist suvorexant, which remained remarkably stable through its
simulations,  the  Nag26  mobile  to  a  degree  that  it  is  difficult  to  compile  a  single
binding mode (Figure 15). The initial docking pose featured a horseshoe-like
conformation similar to suvorexant, but in some simulations, the ligand extends
within the binding site. The dimethylamide group, which lies deep in the binding site
in the initial conformation, retains its position in the pocket lined by Thr5x461, Tyr6x48,
Figure 15. The binding mode of the Nag26 agonist. As the ligand is flexible
throughout the simulations, a collection of the most populated poses is shown.
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Val3x36 and Ser6x52 in the cholesterol-membrane simulations, forming water-mediated
interactions with the Thr5x461. However, the POPC-membrane simulations show the
dimethylamide retreating higher in the binding site, further from the TM5, and then
plunging in-between the TMs4 and 5. This pushes on the side chains of the Thr5x461
and Phe5x43, resulting in a counterclockwise turn of the extracellular end of the TM5.
This  is  perhaps  facilitated  by  the  bulge  at  Thr5x461–Tyr5x47, which tightens in the
process. The rise of the amide group brings the carbonyl to water-mediated
interaction with the Asn6x55 or Arg6x59. Regardless of the dimethylamide, the adjacent
benzene ring remains packed next to Ile6x51, and the linked methoxybenzene is in the
level of Asn6x55 in the middle of the binding site. The methoxy group participates
transiently to interactions with the polar residues from the ECL2 and ECL3, and the
benzene ring packs with the toluenyl group at the other end of the ligand, in the case
of the folded ligand. The sulfonamide moiety is located similarly to the corresponding
structure in the antagonist EMPA (Figure 14), next to the Pro3x29. However, unlike
EMPA in the crystal structure, the Nag26 sulfonamide forms extensive interactions
with polar groups in the TM3 and ECL2–3. Depending on the simulation, it forms
several  transient  direct  or  water-mediated  interactions  with  the  ECL2  and,  again
depending on the simulation, hydrogen-bonds with the Arg6x59 or Lys6x58. In turn,
these  residues  are  often  bound  to  the  acidic  residues  Asp45x51 and  Glu45x52 in the
ECL2. This participation in the cross-binding site bridges seems to tilt the ECL3
towards the ECL2, but it is difficult to say if this is normal fluctuation or a ligand-
induced or a ligand-stabilized conformation. In the 3 μs simulation in the cholesterol
membrane, the ligand retains a deep binding location, which allows direct or water-
mediated hydrogen-bonding between the sulfonamide carbonyls and Gln3x32. The
remainder of the molecule (the central benzene ring, the linker chain and the toluenyl
ring)  is  quite  mobile.  In  some  simulations,  it  retains  or  readopts  the  packed
conformation, which brings the toluenyl ring close to the ECL3 and TM7, especially
the Phe7x34. In contrast, the extended conformation brings the group in contact with
the TM2 and ECL1, and the linker chain under the ECL2, where it forms both direct
and water-mediated hydrogen bonds with the carbonyl of the Cys45x50. Depending on
the “flip” of the toluenyl group, the amide carbonyl is also able to reach Thr2x60.
5.4 Mechanisms of orexin receptor activation
There are multiple links in the chain of GPCR activation. The cascade results
in the opening of the G protein binding site, but as the activation needs to be triggered
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by versatile ligands binding different receptors, the cascades in different receptors
need to differentiate at some point upstream of the G-protein-binding pocket. For the
rhodopsin-like GPCRs, it is suggested that the G protein binding site opening is
mirrored in a defined set of interaction changes upon activation. In Publication III,
we examined our simulations in terms of the conserved inactive and active
interactions at the G protein binding site.26 All simulations maintained the inactive
interactions and, in accordance, none showed the formation of the active interactions.
As we begun the simulations with the receptor in the inactive conformation, the
simulations were perhaps too short for the receptor to undergo a large conformational
change.53–55 Another likely possibility is that the receptor activation event is
energetically slightly unfavorable until the binding of a G protein is able to stabilize
it, and our simulation lengths did not provide a thorough enough sampling to catch
such a “rare” event.
Following the activation cascade upstream, another suggested common event
is the reorganization of the three amino acids called the core triad.29 In the orexin
receptors, the triplet is Phe6x44, Pro5x50 and Val3x40. The core triad usually features a
bulkier residue at 3x40, often isoleucine, and from the Pro5x50 viewpoint, the Phe6x44
lies behind the 3x40 amino acid in the inactive conformation. Upon activation, the
residues reorganize into an equilateral triangle. This reorganization is tied with the
outward movement of the intracellular end of the TM6. In our simulations, the core
triad remains close to the starting (inactive) conformation regardless of the ligand.
The discussion above on the sampling is also relevant here. It is also possible that the
core  triad  function  is  not  conserved  across  class  A  GPCRs.  For  example,  the  M2
receptor  also  features  a  valine  at  3x40,  and  it  shows  near  identical  core  triad
conformations between the active and the inactive crystal structures.30,31 The smaller
residue at 3x40 could pose less of a barrier to the movement of Phe6x44, thus erasing
the distinct inactive and active conformations.
Within the binding site, it is difficult to draw solid conclusions on the
activation determinants, and comparison with other receptors is less fruitful due to
the intrinsic differences between GPCRs. However, one common pattern among
activated GPCRs is the observation that interhelical interactions are often changed.
The ligand might bridge a connection between two helices, which happens in
adrenoceptors for example, or it might break or stabilize direct helix–helix
interactions. As discussed above, the antagonist suvorexant maintains a hydrogen
bond between the Gln3x32 and Tyr7x42. In contrast, the simulations with orexin-A in
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the TM5 binding mode consistently lack this hydrogen bond. Instead, the Tyr7x42
seems to favor binding with the Thr2x60. If the Gln3x32–Tyr7x42 interaction is important
for the receptor inactive state, the alternative binding promoted by orexin-A could
serve to tip  the scales  more in the favor of  receptor  activation.  The Nag26 agonist
does not, however, appear to induce such a strong change in the Tyr7x42 interaction
pattern, but the Gln3x32–Tyr7x42 interaction is less stable nonetheless, in the benefit of
the Tyr7x42–Thr2x60 interaction.
We monitored the polar interactions across the binding site with hopes of
identifying distinct differences between the unliganded, antagonist-bound and
agonist-bound receptors. The simulations did show differences in these bridges, but
they were not correlated with the bound ligand (or a lack thereof). However, the
crystallized orexin antagonists show a distinct lack of interactions with the polar
residues at the rim of the binding site, and our simulations with suvorexant agree with
this. The peptide, on the other hand, traverses between the ECL2 and ECL3 and
perhaps bends to lay atop the receptor, producing extensive interactions with the polar
residues from both loops. Our simulations also show the Nag26 binding a bit higher
than the antagonists, which allows the polar upward facing moieties to form direct
and water-mediated interactions with the ECL2 backbone and acidic side chains. In
addition, the Nag26 agonist interferes in the ECL2–ECL3 salt bridge. These
interactions could serve to pull the extracellular end of the TM6 towards the binding
site, which in turn could pivot the entire transmembrane helix, producing the
canonical outward swing of the intracellular end. The simulations also show Nag26
stably interacting with the Thr5x461, a site of vital importance to adrenoceptor
activation. In two simulations, we observe the Nag26 agonist penetrating between the
TMs 4 and 5, pushing the Thr5x461 in between the helices, inducing a tightening of the
helix bulge at 5x461 and rotating the extracellular end of the TM5. In addition to
affecting the binding-site-exposure of many amino acids, this counterclockwise
rotation also changes the residues present for interhelical interactions with the TMs




6 Conclusions and perspectives
Through peptide docking and molecular dynamics simulations, we produced a
suggested binding mode for the orexin peptides. The binding mode features a water-
bridged network at the bottom of the binding site, linking the exposed main-chain
carbonyls with Gln3x32 and Tyr6x48, both of which are key activation residues among
GPCRs. Leu33 side chain lies in a pocket formed by TMs 5 and 6, Thr32 faces the
TM7, Leu31 is under the ECL1, Ile30 in front of TMs 3 and 4 under the ECL2. Gly29
packs close to His7x38, Ala28 faces TMs 2 and 7 and Ala27 the ECL1. His26 faces the
TM5 and interacts with ECL2 or ECL3, and Asn25 interacts with the extracellular
residues of the TM7. We suggest that the rest of the peptide bends to rest on top of
the ECL2 and TM5, and that the receptor N-terminal amphipathic helix lies on top of
the peptide ligand, shielding the hydrophobic face of the peptide helix II.
Alternatively, the peptide remains upright, and the receptor N-terminal helix adopts
a position parallel to the peptide.
The constraining of the peptide conformation was detrimental to potency. In
accordance to site-directed mutagenesis data, modifications at the C-terminus were
intolerable, whereas modifications at the peptide hinge and at the helix II produced
bioactive peptides. As the Aib-modification carried almost as large effect as the
introduction of the far bulkier staple, it appears that either the binding site is very
confined, the dimehtylated C  blocks key interactions or the modifications stabilize
a conformation, which is incompatible with the receptor.
It would be of high interest to repeat the peptide binding simulations with the
recently discovered N-terminal receptor helix. Such simulation could offer insight
into the functional role of the helix. With hypothetical unlimited resources, an
intriguing setup would also be to construct a simulation, where the peptide was
initially unbound from the binding site, but in interaction with the N-terminal helix.
The suggested binding mode should be validated by introducing new mutations
into the receptors. Especially the ECL3 and the extracellular end of the TM7 would
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